University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

5-2007

Novel Carbopol-Wax Blends for Controlled Release Oral Dosage
Forms
Natarajansoundarapandian Mariageraldrajan
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Pharmaceutics and Drug Design Commons

Recommended Citation
Mariageraldrajan, Natarajansoundarapandian , "Novel Carbopol-Wax Blends for Controlled Release Oral
Dosage Forms" (2007). Theses and Dissertations (ETD). Paper 163. http://dx.doi.org/10.21007/
etd.cghs.2007.0201.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Novel Carbopol-Wax Blends for Controlled Release Oral Dosage Forms
Abstract
Carbopol is crosslinked acrylic acid. Carbopol can be used in developing formulations for transdermal,
oral, rectal use. It is forms strong gel in low concentration. Therefore, it can be used in low concentration
in developing controlled release formulations. This increases the cost effectiveness and number of
formulation options. In spite of its effectiveness, carbopol is one of the most efficient however
underutilized polymer in oral controlled drug delivery system development. This is attributed to the
difficulty in processing the carbopol. Carbopol has poor flow characteristics and stickiness. Objective of
our research is to eliminate processing difficulties of carbopol using hot melt granulation process and to
develop sustained release oral formulations of a basic (Propranolol HCl) and an acidic drug (Glipizide).
Hot melt granulation was used to prepare free-flowing, directly compressible carbopol-wax blends.
Evaluation of granular characteristics of carbopol-wax blends indicated that changes in the granular
characteristics is dependent on process variables such as granulation temperature, granulation time and
mixing speed. At higher granulation temperature, the granulation process became sensitive to granulation
time and mixing speed. Thus, for developing robust granulation process to prepare carbopol-wax blends,
the granulation must be done with lower granulation temperatures.
Carbopol is an acidic polymer and forms complex with basic drugs. Carbopol-basic drug complex has
poor solubility. Hence oral controlled delivery system containing carbopol and basic drug, result in
incomplete drug release. Water uptake and tablet erosion studies confirmed that incomplete drug release
is a result of ionic complexation and absence of tablet erosion. Thus, by selecting appropriate carbopol
grade, extent of ionic complexation was reduced and by using soluble filler in the formulation, an USP
compliant controlled release oral formulation of propranolol hydrochloride was developed.
Controlled release properties of carbopol matrix containing Glipizide were evaluated. Formulations
containing lactose as filler, either had long lag time or burst release based on the concentration of lactose
in the formulation. Formulations containing Avicel yielded tablets with high hardness and zero order drug
release. The drug release pattern of Avicel based formulations was dependent on drug-polymer ratio.
Release of Glipizide from Avicel based formulations was dependent on compression force. Bioequivalent
formulation of Glipzide was prepared using carbopol-wax blend.
Near infrared spectrophotometer was used to predict dissolution profiles of propranolol sustained release
tablets non-destructively. Three different modeling algorithms were compared for their predictability. Knearest neighbors algorithm (KNN) yielded models with better predictability compared to partial least
squares algorithm and support vector machines algorithm. Model validation was performed using
independent data set. Model validation confirmed that KNN models can non-destructively predict
dissolution profiles of sustained release propranolol tablets prepared at two different compression
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ABSTRACT

Carbopol is crosslinked acrylic acid. Carbopol can be used in developing formulations for
transdermal, oral, rectal use. It is forms strong gel in low concentration. Therefore, it can be used
in low concentration in developing controlled release formulations. This increases the cost
effectiveness and number of formulation options. In spite of its effectiveness, carbopol is one of
the most efficient however underutilized polymer in oral controlled drug delivery system
development. This is attributed to the difficulty in processing the carbopol. Carbopol has poor
flow characteristics and stickiness. Objective of our research is to eliminate processing
difficulties of carbopol using hot melt granulation process and to develop sustained release oral
formulations of a basic (Propranolol HCl) and an acidic drug (Glipizide).
Hot melt granulation was used to prepare free-flowing, directly compressible carbopolwax blends. Evaluation of granular characteristics of carbopol-wax blends indicated that changes
in the granular characteristics is dependent on process variables such as granulation temperature,
granulation time and mixing speed. At higher granulation temperature, the granulation process
became sensitive to granulation time and mixing speed. Thus, for developing robust granulation
process to prepare carbopol-wax blends, the granulation must be done with lower granulation
temperatures.
Carbopol is an acidic polymer and forms complex with basic drugs. Carbopol-basic drug
complex has poor solubility. Hence oral controlled delivery system containing carbopol and
basic drug, result in incomplete drug release. Water uptake and tablet erosion studies confirmed
that incomplete drug release is a result of ionic complexation and absence of tablet erosion.
Thus, by selecting appropriate carbopol grade, extent of ionic complexation was reduced and by
iii

using soluble filler in the formulation, an USP compliant controlled release oral formulation of
propranolol hydrochloride was developed.
Controlled release properties of carbopol matrix containing Glipizide were evaluated.
Formulations containing lactose as filler, either had long lag time or burst release based on the
concentration of lactose in the formulation. Formulations containing Avicel yielded tablets with
high hardness and zero order drug release. The drug release pattern of Avicel based formulations
was dependent on drug-polymer ratio. Release of Glipizide from Avicel based formulations was
dependent on compression force. Bioequivalent formulation of Glipzide was prepared using
carbopol-wax blend.
Near infrared spectrophotometer was used to predict dissolution profiles of propranolol
sustained release tablets non-destructively. Three different modeling algorithms were compared
for their predictability. K-nearest neighbors algorithm (KNN) yielded models with better
predictability compared to partial least squares algorithm and support vector machines algorithm.
Model validation was performed using independent data set. Model validation confirmed that
KNN models can non-destructively predict dissolution profiles of sustained release propranolol
tablets prepared at two different compression forces.
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Chapter 1: Introduction

“Patients don’t take drugs, they take dosage forms”.
“All drugs are toxins”.
If we put above sentences together, we will realize that we give toxins to patients using
dosage forms. Sixty years ago, although many scientists agreed that all drugs (toxins) are useful
in curing diseases, not many scientists realized the dosage forms can offer distinct advantages
such as reducing toxicity, extending therapeutic efficiency of drugs etc. However, now all
pharmaceutical scientists and patients agree that pharmaceutical dosage forms make distinct
difference in patient health care.
In last five decades, scientists have developed many types of delivery systems each with
unique advantages. One of the oldest drug delivery systems is oral drug delivery systems. Oral
drug delivery systems are popular far more than a century due to many distinct advantages such
as ease of administration, palatability, ease of manufacturing, high patient compliance compared
to parentral administration, no need for hospitalization etc.
Oral delivery systems include tablets, capsules, and molded pills. Since most of the drugs
are available as solids and the stability of drugs is high at solid state, solid oral drug delivery
systems are the most popular category of oral drug delivery systems among pharmaceutical
scientists who explore use of different delivery systems for patient use. However, oral drug
delivery systems are not “cure for all” technique. Modifications in the design of delivery system
may be required based on needs. Needs may be different for each case.
One of the most profound needs is to maintain drug concentration in systemic circulation
for longer period of time. This is one of the most desirable properties of an ideal drug delivery
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system. For, it reduces the frequency of administration and reduces the toxic effects of the drug.
This objective can be achieved by formulating the drug in controlled release dosage form.
Although there are multiple ways of designing delivering controlled release dosage forms, oral
controlled drug delivery is one of the most popular and oldest techniques available. There are
different types of oral controlled drug delivery systems available. They differ in the methods of
manufacture, components of the system, method of administration etc.
One of the widely used classifications of oral controlled drug delivery systems involves
use of mechanisms of drug release. This includes (i) dissolution controlled, (ii) diffusion
controlled, (iii) ion exchange controlled, (iv) solvent controlled. Controlled release properties of
oral drug delivery systems are imparted and optimized by selection of appropriate ingredients in
the formulations. One of the most commonly used ingredients in formulation is a slowly
dissolving gel forming polymer. Development and optimization of controlled drug release
systems mandate understanding of gel forming polymers, their interactions with drugs and other
matrix ingredients with different solubility, permeability, ionic characteristics etc. Some basic
understanding of each type of oral controlled drug delivery system is discussed here:

1.1. TYPES OF ORAL CONTROLLED DRUG DELIVERY SYSTEMS

1.1.1. Dissolution controlled drug delivery systems
These types of systems employ dissolution control of active drug as release mechanism.
This is one of the simplest types of systems. There are two types of dissolution controlled
systems. They are (i) encapsulated products, (ii) matrix products.
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In the encapsulated products type, the active drug is coated with a slowly dissolving
polymer or a wax. This coating controls the exposure of drug to the dissolution media. Since the
availability of the dissolution media for dug dissolution is controlled, the release of the drug from
coated particles is slow.

1.1.2. Diffusion controlled systems
Diffusion controlled systems employ control over drug diffusion from the device as
opposed to the control over drug dissolution of dissolution controlled systems. Diffusion
controlled systems are useful for drugs with poor solubility while dissolution controlled systems
are useful for drugs with high solubility. There are two types of diffusion controlled systems.
They are (i) reservoir devices, (ii) matrix devices. In reservoir devices, a drug core is surrounded
by a polymeric membrane. In matrix devices, the active drug is dissolved or dispersed in
polymeric matrix.
There are differences in mechanism of release kinetics followed by reservoir and matrix
devices. While the drug release from reservoir devices can be explained by Fick’s law, matrix
devices follow Higuchi’s equation.

1.1.3. Ion exchange resins
Unlike dissolution and diffusion controlled systems, the mechanism of drug release from
ion exchange resins is different and depends on the exchange of ions between the dissolution
media and the availability of exchange sites of the resins. First, the drug is complexed with the
ion exchange resin, by exposing the saturated drug solution to calculated quantities of ion
exchange resins. Then this product is either suspended or encapsulated in capsules for
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administration. Upon administration, the ions in the dissolution media (biological fluids in gastro
intestinal tract) are exchanged. As a result, drug ions are replaced by the ions in the dissolution
media. This replacement releases drug from ion exchange resins to biological fluids.

1.1.4. Solvent controlled systems
These systems employ control over solvent uptake of the system as opposed to
controlling the dissolution or diffusion of the drug. Thus, these types of systems can be suitable
for drugs wide differences in solubility. There are two mechanisms by which solvent controlled
systems exercise control over the drug release. They are (i) osmosis, (ii) swelling.
Osmotic controlled systems have three basic components: (i) semi-permeable membrane,
(ii) osmogen, (iii) delivery orifice. Semi-permeable is generally made up of cellulose acetate. It
has selective permeability. The semi permeable membrane is designed in such a way that only
water can permeate into the device and drug can not diffuse out of the device. The core of the
device is coated with the semi permeable membrane. The core contains the drug and osmogen.
Osmotic agents increase the osmotic pressure created, due to the dissolution of drug, inside the
device. At high osmotic pressure, the contents of core are released through the delivery orifice.
By optimizing the thickness of semi-permeable membrane, concentration of osmogen, diameter
of the delivery orifice the drug release can be programmed precisely.
Next type of solvent controlled systems is swelling controlled system. Swelling
controlled systems are one of the most extensively studied and utilized systems. This system
consists of polymers that can swell in aqueous environment. Polymers that are used to prepare
swelling controlled systems are generally called hydrogels. There are two types of hydrogels (i)
water soluble, (ii) water insoluble. Both of these types absorb lot of (more than 100% of its
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original weight) water and form gel like structure in aqueous media. The viscosity and the
resistance to drug permeability of these gels formed in aqueous media contribute to hydrogel’s
ability to control the drug release.
There is another classification of hydrogels based on its origin. This classification
includes three types (i) natural, (ii) semi-synthetic, (iii) synthetic. Examples of each category are
i. Natural: gelatin, dextran, collagen, fibrin, chitosan, alginate.
ii. Semi – Synthetic: hydroxy propyl methyl cellulose, hydroxy ethyl cellulose, hydroxy
propyl cellulose, ethyl cellulose.
iii. Synthetic: acrylic acid derivatives (Carbopol®, Eudragits®), hydroxy ethyl methacrylate,
N-vinyl-2-pyrrolidone.

1.2. HYDROGEL BASED ORAL CONTROLLED DRUG DELIVERY SYSTEMS
As mentioned earlier, considerable attention is given to matrix controlled oral devices
prepared using hydrogels because of their advantages. They are
i. Ease in processing. Systems containing swellable polymers have excellent compressibility
and flowability characteristics. These two are prerequisites for routine manufacturing of
tablet dosage forms.
ii. High drug loading. It is possible to develop systems with wide variety of drug loadings
however with a significant control on the tablet size. This increases the formulation
options.
iii. Design flexibility. Single or combination of polymers can be used to formulate the system.
Polymers with different characteristics can be combined in a system to achieve unique
advantages of the system.
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1.2.1. Mechanism of drug release from hydrogels
As mentioned earlier, hydrogels can absorb large quantities of water. So, their release
mechanism is completely different from hydrophobic polymeric systems that release drug
through pore diffusion process. In general, one of the following three modes of drug release is
observed in hydrogel based formulations
i. Diffusion controlled.
ii. Swelling controlled.
iii. Chemically controlled.
Diffusion controlled systems can be explained using Fick’s law with constant or variable
diffusion coefficients.
Swelling controlled release from hydrogels is observed when the drug release is faster
than hydrogel swelling. Typically, polymers used in these systems exist in glassy and rubbery
states. These states of polymer define the boundaries in the delivery system. Modeling of drug
release from these systems involves these boundary conditions. Two types of boundaries are
observed in swelling controlled system. They are erosion boundary and swelling boundary.
Erosion boundary is observed between the swollen gel layer and the dissolution media. Swelling
boundary is observed between ungelled core (glassy polymer) and gelled layer (rubbery
polymer). Distance between erosion boundary and swelling boundary is thickness of gelled layer.
Ungelled layer of the tablet is called glassy core. The drug release depends on the thickness,
viscosity of gelled layer and its interaction with drug molecules.
Chemically controlled release depends on chemical reaction within the matrix. For, the
drug molecule is chemically attached to polymer chains. Thus, hydrolytic or enzymatic cleavage
must set the drug free to be released. In some cases, surface or bulk erosion of polymers may aid
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drug release. Although this approach of chemically attaching drugs to polymer is popular
research area, due to the regulatory restrictions it lacks market potential. Scientists have shown
chemical cross linking can yield controlled release formulations that can release drug for
multiple years with constant release rate. However, Food and Drug Administration considers an
established drug as new molecule after any chemical modifications. This poses threat to very
existence of the drug in the market and may need multi million dollar investments to get this
product approved.
Understanding of drug release mechanisms from delivery system helps us to predict the
extent of drug release based on the type of the system and polymers used to control the drug
release. Modulation of drug release is possible only if the factors controlling the drug release are
precisely understood. In an effort to understand the drug release mechanisms, many scientists
have developed empirical and semi-empirical mathematical models explaining drug release.
There are few processes associated with drug release from polymeric systems. As these
processes determine the drug release, they are pivotal in understanding of the drug release
characteristics of polymeric systems. These processes are (i) water uptake, (ii) polymer chain
relaxation with volume expansion (swelling), (iii) drug diffusion, (iv) dissolution of polymer
(erosion). In most cases, more than one of these processes takes place simultaneously. This
creates a complex scenario. As these processes are time dependent, changes in the drug release
can not be predicted accurately using a single mathematical model. However, closest
approximations can be made using an appropriate model.
In general, diffusion, swelling and erosion are the important rate limiting mechanisms in
most of the drug delivery systems. Diffusion can be explained using Fick’s law. With onedimensional transport assumption, valid simple mathematical models can explain the drug
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release. This model is valid only for flat, planar devices. However, tablets are three dimensional
powder compacts thus this simple model can not be used and may require complex mathematical
models to explain/predict the drug release. Complexity in modeling such devices can be reduced
by assuming constant diffusivity. However diffusivity is a function of water content of the
system. Water content of the system changes with time invalidating the constant diffusivity
assumption. Thus models based on constant diffusivity are less useful.
Polymer dissolution adds one more dimension to the problem that is already complex.
Polymer dissolution will change the boundary conditions that are basically defined for explaining
diffusion. Thus moving boundary conditions must be accounted in modeling such systems. Drug
solubility may be another variable that can change the drug release mechanism. Drug solubility
is an important factor when systems containing poorly soluble drugs are modeled.
In general, overall drug delivery process from swellable polymers e.g. HPMC, Carbopol
can be described as follows.
i. Water concentration gradients are formed at polymer-water interface. This results in
imbibition of the water into the matrix. This process depends on the physical status of the
system. In dry systems the diffusion coefficient is low, where as in swollen gels it is similar
to that of pure water. Water acts as a plasticizer and reduces the glass transition
temperature of the polymer. Once the concentration of water is high enough to reduce the
glass transition temperature to the temperature of the system, the polymer chains undergo
transition from glass to rubbery state.
ii. Water imbibition causes polymer swelling and results in dimensional changes of the
system. Geometric dimensions of the system increase as a result of swelling.
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iii. Contact of water with the drug in the system aid the dissolution of the drug and the
dissolved drug diffuses out of the system.
iv. Continuous water penetration increases water content in the system. Increasing water
content substantially increases the diffusion coefficient.
v. Poorly soluble drugs don’t dissolve freely in the available water in the system. Thus,
coexistence of dissolved and undissolved species of drug can be observed. However, non –
dissolved drug does not diffuse out.
vi. Systems containing high loading of freely soluble drugs undergo structural changes as drug
diffuses out. As drug diffuses out the matrix becomes more porous and offers less
resistance to the remaining drug in the matrix.
vii. Depending on the polymer type, extent of cross linking, degree of substitution the polymer
dissolves slowly or rapidly. If the entire drug is released before any significant reduction in
polymer content due to its dissolution, then this phenomenon is less important.

1.2.2. Empirical and semi-empirical mathematical models

1.2.2.1. Higuchi equation
In 1961, Higuchi published a mathematical equation to describe drug release from matrix
systems [1]. Although it was valid for planar systems initially, it was later modified to include
different geometries and matrix characteristics. Higuchi equation was derived under pseudosteady state assumptions and has less practical use when “real” controlled delivery system is
modeled. The basic equation of Higuchi model is:
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Mt/A = √ D (2Co-Cs)Cst

(Eq. 1.1)

Where Mt is the cumulative absolute amount of drug released at time t, A is the surface area of
the controlled release device exposed to the release medium, D is the drug diffusivity in the
polymer , Co is initial drug concentration and Cs is the solubility of the drug in the polymer. This
equation can be written as:

Mt/M∞ = K√t

(Eq. 1.2)

Where M∞ is the absolute cumulative amount of the drug released at the infinite time (equal to
the drug loading in the system at time t=0) and K is a constant for design variables of the system.
Thus, drug release at any given time is proportional to the square root of the time. Most
attractive feature of this Higuchi equation is its simplicity and applicability to many cases.
However, we must be mindful of Higuchi equation when it is used. The assumptions are
i. Initial drug concentration in the system is much higher than the solubility of the drug. This
assumption forms basis for pseudo-steady state approach.
ii. One dimensional diffusion forms basis of mathematical treatments used in the equation.
Thus, equation is valid only if the edge effects must be minimal.
iii. Particle size of the suspended drug must be much smaller than the thickness of the system.
iv. Swelling and/or polymer dissolution must be negligible.
v. Drug diffusivity remains constant throughout the drug release period.
vi. Perfect sink conditions are maintained.
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Evidently, these assumptions are invalid in most of the drug delivery systems. However,
Higuchi equation can be used to get an abstract idea of underlying release mechanism.
Simultaneous occurrence of many effects such as swelling, transition from glassy to rubbery
state, polymer dissolution, water diffusion in and out of the system, drug diffusion out of the
system may result in pseudo square root time kinetics. In general, proportionality between
cumulative amount of drug released and square root of time is regarded as an indicator of
diffusion controlled drug release.

1.2.2.2. Power law
Power law is a semi-empirical equation to describe the drug release from polymeric
systems.

Mt/M∞ = ktn

(Eq. 1.3)

Mt is cumulative amount of drug released at time t, M∞ is cumulative amount of drug released at
infinite time, k is release constant incorporating structural and geometric characteristics of the
system, and n is the release exponent indicating the mechanism of drug release.
Peppas and co-workers [2, 3] not only introduced this equation but also explained uses
and cautioned about its limitation. Power law is generalization of two independent drug release
mechanisms. They are Fickian diffusion and Case II transport [4, 5]. In most systems containing
swellable polymers, the drug release is additive result of polymer relaxation and diffusion [6].
Thus, power law gets one step closer to “reality” compared to Higuchi equation.
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Release exponent ‘n’ in the power law takes multiple values based on geometry of the
system. By default the value of ‘n’ is 1. This indicates that drug release is independent of time, in
other words, zero order drug release or case-II transport. In this case, water imbibition is the rate
limiting step in the drug release. As described earlier, water can act as plasticizer and change the
physical state of the polymeric system from glassy to rubbery state. These transitions not only
cause volumetric expansion of the system but also increase the mobility of the drug molecules.
When power law assumes 0.5 as the value of ‘n’ then it indicates diffusion controlled
drug release, if the value of n=1.0 then it indicates swelling controlled drug release. If the values
of ‘n’ are between 0.5 to 1, then it indicates combination of both diffusion and swelling
mechanisms. This superimposition of both diffusion and swelling mechanisms is called
anomalous transport. It must be remembered that these values are valid only for slab geometry.
‘n’ values for spheres and cylinders [7, 8] are given in the Table 1.1.

1.2.2.3. Other empirical and semi-empirical models
Another mathematical model was developed by Peppas and Sahlin [9]. This is an
extension of power law equation. It is

Mt/M∞ = k1tm +k2t2m

(Eq. 1.4)

Where k1, k2 and m are constants. First term in the right hand of the equation represents the
contribution of fickian diffusion (F) to overall drug release and the second term represents
relaxational contribution (R). R/F ratio can be calculated using following formula
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Table 1.1. Release exponent values for devices of different geometry

Release exponent (n)

Release mechanism

Slab

Cylinder

Sphere

0.5

0.45

0.43

Fickian diffusion

0.5<n<1

0.45<n<0.89

0.43<n<0.85

Anomalous transport

1.0

0.89

0.85

Case-II transport
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R/F = k2tm/k1

(Eq. 1.5)

R/F ratio can be used to identify the dominant release mechanism at any given time during the
drug release. This can help to modulate the release profiles based on appropriate release
mechanisms.
Thus far, this review of controlled drug delivery systems with emphasis on oral
controlled drug delivery systems illustrated the mechanisms of drug release, materials used for
preparation of swelling controlled oral controlled delivery systems. One of the most efficient
however under utilized polymer that can be used to prepare oral controlled drug delivery systems
is carbopol.

1.3. ORAL CONTROLLED DRUG DELIVERY SYSTEMS BASED ON CARBOPOL
Carbopol is polymers of acrylic acid crosslinked with allyl sucrose or allylpentaerythritol.
Among multitude of polymers available in market, carbopol offers unique advantages when used
in oral controlled release formulations [10]. They are
i. Systems containing carbopol as their major release controlling polymer show linear drug
release (zero order release kinetics) for drugs with wide differences in solubility and doses.
ii. Carbopol is an excellent bioadhesive. Bioadhesivness of carbopol helps the drug delivery
system by increasing the gastro intestinal transit time. Increase in gastro intestinal time
improves the bioavailability and helps to achieve complete drug release from the dosage
form.
iii. Carbopol forms a strong gel at low concentrations. High gel strength helps to achieve
desired drug release profiles with low polymer concentration. Usage at low concentrations
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will increase cost benefits of delivery system, effective sustained release formulation can
be designed with smaller size tablets and more formulation options will be available.
iv. Carbopol is synthetic polymer. Being synthetic, carbopol provides consistency in drug
release profiles.
v. Carbopol has excellent compressibility. It forms hard tablets even with low compression
forces.
As mentioned earlier, carbopol is one of the under utilized polymers in oral controlled
drug delivery system development. Its usage is less compared to other cellulose polymers.
However, there are studies [11-22] showing effectiveness of carbopol alone and in combination
with other polymers to develop sustained release tablet formulations.

1.3.1. Properties of carbopol

1.3.1.1. Physical and chemical properties of carbopol
Carbopol is high molecular weight polymer. It is acrylic acid derivative prepared by
chemical crosslinking with polyalkenyl alcohols or divinyl glycol. It is available as flocculated
powders with average particle diameter of 0.2 micron. Surface static charge cause aggregation of
submicron size particles. These particle aggregates can have particle size upto 2 to 7 microns.
Essentially, each particle can be visualized as polymeric network containing polymer
chains inter connected with multitude of cross links. Each polymer particle is capable forming
strong gels when in contact with water and represents all properties of polymer. This unique
property explains the efficiency of carbopol as controlled release polymer at significantly lower
concentration compared to cellulose polymers. The polymer properties are controlled by degree
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of crosslinking which is dependent on amount of cross linker used during its preparation. Precise
control over the extent of crosslinking adds consistency in the property of polymers unlike
natural or semi – synthetic polymers. Cross linked polymers are insoluble in water however
swellable in water. Most commonly used cellulose polymers such as Methocel® and Klucel®
are uncrosslinked, linear polymers. They are water soluble and control drug release by swelling
and erosion.
When in powder form with low water content (2 to 4%), the glass transition temperature
of Carbopol is 105oC. However, the glass transition temperature drops dramatically when the
polymer comes in contact with water as water is a good plasticizer for Carbopol. Plasticization of
carbopol by water causes gyration of polymer chains. Radius of gyration continues to increase
with time. Increase in radius of gyration, increases end-to-end distance of polymer chains,
resulting in swelling of polymer. Carbopol can swell up to 1000 times its original volume and
swelling is dependent on the pH of the aqueous media. Carbopol reaches its maximum swelling
when pH of the environment is above its pKa of 6±0.5.

1.3.1.2. Molecular weight of carbopol
It is impossible to measure accurate molecular weight of carbopol because of its
extensive crosslinking. All analytical methods used for molecular weight determination require
solubility of polymer as the measurements are made in dilute polymer solutions. Extensive
crosslinking of the polymer chains make carbopol water insoluble hence impossible to estimate
its molecular weight using conventional methods. However, using stoichiometric and theoretical
calculations, molecular weight of carbopol can be estimated. It is calculated to be 3.5 billion.
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This high molecular weight is attributed to hundreds of polymer chains interconnected with cross
links in a polymer molecule.
In linear polymers molecular weight and viscosity of the polymers are important factors
controlling the drug release. However, in cross linked polymers like carbopol, they are
unimportant. Nevertheless, the extent of crosslinking is important release controlling factor.

1.3.1.3. Carbopol grades and their properties
Introduced in mid 1960, carbopol is available in various grades. These are carbopol 934P,
carbopol 974P NF, carbopol 971P NF and carbopol 71G NF. Carbopol 934P was one of the
earliest grades of carbopol introduced to pharmaceutical market. However, benzene was used in
crosslinking process in the preparation of 934P. Following toxicological concerns of residual
benzene in carbopol 934P, pharmaceutical grades prepared with ethyl acetate were introduced.
These are Carbopol 974P NF, carbopol 971P NF and carbopol 71G NF. Letter “P” in the name
of carbopol grade indicates that this particular grade is suitable for pharmaceutical use. Letter
“G” in the carbopol name indicates that this particular grade is available in granular form. Unless
specified, all pharmaceutical grade carbopols are available as powders. All pharmaceutical grade
carbopols have strong binding characteristics making them suitable for direct compression
formulations. However, powder grades must be used in lowest necessary concentration in direct
compression formulation as they have poor flowability. Nevertheless, granular grades have good
flowability and can be used in high concentrations in direct compression formulations.
Carbopol 974P and 934 P have similar rheological characteristics. In spite of their similar
rheological characteristics, they show different release characteristics when used in the tablets at
same concentrations. Carbopol 934P provides near zero order release profile through out the
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gastrointestinal tract, while carbopol 974P provides semi-enteric release profiles i.e., slow
release in stomach and faster release in intestine. Analogically, based on their viscosity
characteristics, carbopol 934P and carbopol 974P can be compared to mayonnaise and carbopol
971P can be compared to honey. Carbopol 971P is less crosslinked than 974 P. Carbopol 971P
provides slow but more linear release than 974P. Carbopol 71G is granular form of 971P.
Carbopol 71G has no chemical additives and prepared using roller compaction of carbopol 971P.
Carbopol 71G has better flow characteristics than Carbopol 971P.

1.3.2. Drug release characteristics of carbopol matrix

1.3.2.1. Mechanism of drug release from carbopol matrix
Carbopol based matrix has stark contrast in drug release mechanism compared to matrix
containing cellulose based polymers such as Hydroxy Propyl Methyl Cellulose (HPMC),
Hydroxy Propyl Cellulose (HPC), Hydroxy Ethyl Cellulose (HEC) etc. Cellulose based polymers
are water soluble linear polymers. They form gel layer on tablet surface upon hydration.
Thickness, strength of the gel layer depends on molecular weight, polymer concentration and
viscosity characteristics of gel layer. At higher polymer concentration, proximity of linear
polymer chains increases probability of chain entanglement. Entangled polymer chains offer
more resistance to drug release compared to individual polymer chains. Thus, drug release is
inversely proportional to polymer concentration. Since cellulose based polymers are water
soluble, swollen gel layer dissolves (erodes) away from the matrix. The extent of erosion
depends on viscosity of the polymer which in turn depends on the molecular weight of the

18

polymer. Thus, polymer with higher molecular weight releases drug slower compared to its low
molecular weight counterpart.
Controlled release properties of carbopol marix are related to less extent with its
molecular weight and viscosity and dependent on carbopol concentration in the matrix.
Controlled release mechanism of carbopol matrix is dependent on extent of gellation and
swelling. Extent of polymer swelling is dependent on degree of crosslinking and pH of the
dissolution media. When in dry state, drug is entrapped in polymeric matrix in its glassy state.
Upon contact with water, the glass transition temperature of polymer lowers below the external
temperature turning the polymer from glassy state to rubbery state. In rubbery state, the mobility
of polymer chains is high compared to that of polymer in its glassy state. However, chain
entanglement due to increase in chain mobility is dependent on extent of cross linking. Carbopol,
as described earlier, has individual polymer particles which are composed of polymer chains
attached by crosslinks. Thus, each particle turns into gel in which the drug is dispersed.
Crosslinks enhance ability of gel-particles to entrap the drug molecules.
Carbopol hydrogels are water insoluble unlike cellulose hydrogels. Thus, carbopol gels
don’t erode. However, they absorb lot of water and create osmotic pressure inside the gel. When
fully hydrated, the osmotic pressure will break up the structure and shed off individual pieces of
hydrogels. This unique property contributes carbopol’s ability to release drug in near zero order
fashion for long time [23-31]. It is hypothesized that upon gelling the surface of the polymer
particles has gel layer. When glassy polymer turns into rubbery, hydrogel particles are formed.
Each hydrogel particle can entrap the drug and form a drug reservoir. It can be imagined that
hydrogel particle having drug is surrounded by swollen gel layer. Since the drug concentration is
high in the hydrogel core, the thermodynamic activity of the drug increases and releases the drug
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from hydrogel. Swollen gel layer at surface of the hydrogel acts as rate controlling membrane
thus helping to achieve linear drug release from hydrogels.
Since drug release from carbopol matrix depends on its hydrogel structure, factors
influencing hydration and swelling of carbopol hydrogel can influence the drug release.
Hydration and swelling of carbopol is dependent on crosslink density, extent of chain
entanglement and crystallinity of the polymer. Rate of swelling is dependent on pH of the
medium. Carbopol is an acidic polymer. It swells faster in alkaline pH compared to acidic pH.
Since each polymer particle is capable of forming hydrogel, the channels in the hydrogel is
dependent on the concentration of polymer. Increase in polymer concentration will decrease the
diameter of channels in the hydrogel and decrease the drug release. Thus, polymer concentration,
extent of crosslinking, pH of the dissolution media can significantly influence the hydrogel
properties hence drug release.
As mentioned earlier, thermodynamic potential of the drug is the chief driving force for
the drug diffusion from carbopol hydrogel. Thermodynamic potential of the drug is a function of
its solubility. Drugs with poor solubility will have poor thermodynamic potential and may
partition into the hydrophobic domains of the hydrogels. Acrylic backbone of carbopol forms
hydrophobic domain of the system. Thus, incase of poorly soluble drugs, drug partitioning may
support carbopol’s ability to control the drug release. Absence of matrix erosion provides
stability for the carbopol matrix for longer period of time. Combination of these properties
results in linear drug release profile of poorly soluble drugs from carbopol matrix. In contrast,
cellulose based polymeric systems will show fickian release pattern with poorly soluble drugs.
This is attributed to solubility of cellulose matrix. In case of highly water soluble drugs, fickian
diffusion is observed with carbopol matrix. Although this behavior is similar to that of cellulose
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polymer, it is not due to the solubility of the matrix. It is attributed to quick dissolution of the
drug or drug partition in to aqueous, low viscosity regions of the carbopol gels. Carbopol grades
with high crosslinkinks e.g. Carbopol 974P offer large interstitial spaces where water is filled.
Thus highly soluble drugs can quickly dissolve in these water filled channels and diffuse out of
the matrix. In contrast, carbopol with less crosslinks e.g. Carbopol 971P form hydrogel with
more uniform gel structure and less extent of water filled channels. Therefore, carbopol 971P is
more effective than carbopol 974P in controlling drug release of freely soluble drugs. This is
attributed to less number of interstitial channels and more uniform gel structure.
Compared to cellulose polymers, it is sometimes beneficial to use carbopol based systems
for poorly soluble basic drugs. According to Henderson-hasselbach equation, the basic drugs
have maximum solubility in acidic pH values. Thus, if cellulose polymers are used in
formulating basic drugs, then acidic salts must be used in the formulation to solubilize the drug.
Otherwise the drugs will precipitate in the tablet and will not be released to the fluids in GIT.
However, carbopol is an acidic polymer. So, carbopol based sustained release matrix has acidic
micro environment. Thus, it requires no acidic salt to maintain an environment to solubilize the
drug.
Carbopol based tablets show limited erosion at high (more than 10%) polymer
concentration. This is attributed to entanglement of polymer chains resisting de-aggregation of
polymeric matrix. Carbopol is water insoluble due to its extensive cross linking. Absence of
matrix erosion and insolubility makes carbopol matrix very robust to wide differences in gastric
motility, pH and fluid content in the gastro intestinal tract. Besides, tablets prepared using high
compression forces are likely to have less interstitial space. This leads to reduction in number of
channels for drug diffusion and result in decrease in drug release.
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1.3.2.2. Crosslink density and drug release from carbopol matrix
As discussed earlier, gel structure and drug characteristics are the most important factors
that influence the drug release characteristics of carbopol matrix. Gel structure is dependent on
the extent of crosslinking and differences in micro and macro viscosities of gel structure.
Upon hydration, carbopol 971P, grade with low crosslink density, forms “fishnet” gel
structure. Low crosslinking permits polymer chains to open up as there is less constraints on the
polymer structure. As the polymer opens freely upon hydration, the interstitial spaces are
virtually eliminated and uniform gel is formed. This implies that there is less difference in the
viscosity between micro and macro viscosity regions of the gel. This homogenous gel structure
offers high resistance to drug diffusion compared to grades with high degree of crosslinking.
Thus, carbopol 971P may be more efficient at lower concentration compared to carbopol 974 P
in controlling drug release.
Carbopol 974P, grade with high crosslink density, forms gel with “fuzzyball” structure.
High number of cross links constrains the polymer swelling upon hydration. Therefore, the
polymer does not open up leading to high difference in the viscosities of the different regions in
the carbopol gel. These regions are called micro and macro viscosity regions based on their
viscosity. Micro viscosity region has gel with low viscosity and macro viscosity region has gel
with high viscosity. The differences in the gel viscosity stems from the differences in the water
content in different regions of the gel. In carbopol 974P, since the polymer chains don’t open up,
they form gels with wide differences in viscosities of micro and macro viscosities.
Thus, in essence, carbopol gels are non-homogenous. They have micro and macro
viscosity regions. Differences in the viscosity of micro and macro viscosity regions depend on
the degree of crosslinking. Carbopol grades with high cross link density show higher differences
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in their viscosity between micro and macro viscosity regions while carbopol grades with low
cross link density show lower difference in their viscosity between its micro and macro viscosity
regions. The differences in the gel characteristics also imply that carbopol 974P forms rigid gel
microparticles while carbopol 971P forms flexible gels when hydrated. Although carbopol 974P
forms rigid gel particles, the drug release from carbopol 974P gels is higher compared to
carbopol 934P and carbopol 971P. This is attributed to the higher number of channels present in
their gel structure.
In simulated gastric fluid, carbopol gels are not fully hydrated. Based on their controlled
release properties in the desending order, the carbopol grades can be arranged as carbopol
971P>carbopol 934P> carbopol 974P. In simulated intestinal fluid or in a media with pH > 6, the
carbopol gels are fully hydrated. In fully hydrated states, based on their controlled release
properties in the desending order, the carbopol grades can be arranged as carbopol
971P>carbopol 934P> carbopol 974P. The differences in the controlled release properties among
different carbopol grades are attributed to their gel structure, differences in the number of
channels in the gels formed etc. Carbopol 974P gels form rigid gel particles with more number of
particles upon full hydration. Thus, when drug dissolves in the dissolution media, rigidity of the
gel particles resist drug diffusion into the gel particles. This leads to accumulation of drug
particles in interstitial spaces between gel particles. As these interstitial spaces turn into water
filled channels over time, it results in high drug release. Carbopol 971P gels form flexible gels
with less number of channels. Thus, when drug dissolves they can diffuse into gel particles. The
uniform gel viscosity and less number channels resist the drug diffusion out of the gels.
Therefore, drug diffusion into the gel structure is the rate controlling factor in drug release from
carbopol gels and it is dependent on extent of crosslinking.
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1.3.2.3. Effect of drug solubility on drug release from carbopol matrix
Mostly carbopol polymer shows extended release profiles when fully hydrated when
loaded with drugs with moderate water solubility i.e., less than 100mg/ml). Nature of drug
release profiles is dependent on the degree of crosslinking, water solubility of the drugs and pH
of the dissolution medium. Table 1.2 summarizes the effect of these factors on the pattern of
drug release
In general, water soluble drugs exhibit square root time release kinetics in both simulated
gastric fluid and simulated intestinal fluid in all three grades of carbopol. However, poorly water
soluble drugs exhibit near zero order release profiles in carbopol 934P and carbopol 971P and
they show semi-enteric (less amount of drug released in acid and more amount of drug released
in phosphate buffer) profile in carbopol 974P.
Highly water soluble drugs like norephedrine HCl [32] from carbopol matrix are released
through partition. Thus, drug dissolution is the release controlling mechanisms in such cases.
Once dissolved the drug partitions into low viscosity region in the microstructure and released
through channels.
Perez-Marcos et al [30, 31] compared the release mechanisms of carbopol matrix for
drugs with different solubility. Highly water soluble drug, atenolol, exhibited square-root-of-time
dependent drug release while poorly water soluble drug, furosemide, exhibited zero order
release. Huang et al [33] studied the effect of drug solubility on carbopol 934P matrix.
Theophylline, a poorly soluble drug, exhibited fickian diffusion in SGF. Water soluble drugs,
such as chlorpheniramine maleate and sodium salicylate, exhibited fickian diffusion in SGF.
These studies confirm the significant relationship between drug solubility and drug release
pattern from carbopol based matrix systems.
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Table 1.2. Relationship between carbopol grade and drug release mechanisms

Highly water soluble drugs

Poorly water soluble drugs

pH = 1.2

pH = 7.5

pH = 1.2

pH = 7.5

934P NF

Fickian

Fickian

Non-fickian/
Anomalous

Anomalous/
Case II

971P NF

Fickian

Fickian

Non-fickian/
Anomalous

Anomalous/
Case II

974P

Fickian

Fickian

Non-fickian/
Anomalous

Fickian

Carbopol grade
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It is postulated that if the barrier controlled mechanism is predominant than diffusion,
then a zero order drug release pattern is observed in carbopol matrix. In cases where zero order
or near zero order release is observed, hydrated polymer may act as physical barrier for drug
diffusion or polymer relaxation could slower the drug release.

1.3.2.4. Effect of pH on drug release
Carbopol is weakly acidic polymer. The maximum swelling of the polymer is achieved in
basic pH. Oral controlled release formulations first reside in stomach before reaching intestine
where the pH is basic. Acidic stomach pH does not support carbopol gelling. Thus with most
drugs fickian release pattern is observed in stomach pH. Basic intestinal pH supports complete
swelling of carbopol as it causes ionization of carboxylic acid groups. Ionization of carboxylic
acid groups in polymer chains result in repulsion of polymer chains which is manifested as
polymer swelling.
Upon complete hydration and swelling, carbopol polymers exhibit a special type of nonfickian anomalous release with poorly soluble drugs. It is called case II or near zero order drug
release. It is attributed to formation of gel barrier and gel micro particles in carbopol based
matrix systems. This is called barrier controlled release mechanism. Upon hydration, gel micro
particles trap the drug inside the particles. Surface gel layer act as barrier coating controlling the
drug release. As the drug particles are solubilized, their thermodynamic potential migrate the
solubilized drug to the surface gel barrier. Now, Surface gel barrier contains saturated drug
solution and maintain the concentration gradient required for uniform drug release. Drug diffuses
out from saturated gel barrier to channels in the micro viscosity regions of the carbopol matrix.
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Since each gel micro particle can serve as drug reservoir, this process of uniform drug release
adds up and results in zero order drug release from the matrix.
F. Bulut-Oner et al [34] used isoniazid, a water soluble drug, with 30% carbopol 934P
matrix to study the effect of pH on the drug release characteristics. While all drug was released
in less than fifty minutes in SGF, the drug release was sustained for seven hours in SIF and
sustained for five hours in distilled water. Thus, at neutral and near neutral pH boosts the
efficiency of carbopol matrix to sustain the drug release.
Study by A.M. Cooper et al [32] illustrate the effect of pH on the drug release with
carbopol matrix is not without exceptions. Testing basic CNS compounds in HPMC and
Carbopol 974P matrices, authors confirmed similar fickian diffusion type release profiles with
carbopol matrix in both SGF and SIF. This implies that nature of drug plays critical role in drug
release characteristics of carbopol matrix. Thus, whenever the effect of pH on the drug release
from carbopol matrix is discussed, it must be done in context to the nature of drug.
Another special case is carbopol matrix containing ionizable drugs. Carbopol is an
anionic polymer. In basic pH, carboxylic acid groups of carbopol ionize and the gel fully
hydrates. Basic drugs undergo complexation with anionic carbopol when both drug and carbopol
are ionized. In most cases, the drug – carbopol complex has less solubility than the pure drug.
This supports carbopol’s sustained release properties. Therefore, pH independent, zero order
release profiles are observed for basic compounds in carbopol matrix. Carbopol has carboxylic
groups to the extent of 62%. This makes basic drugs most vulnerable for complexation [35, 36].
Complexation not only provides pH independent drug release but also results in incomplete drug
release. Thus, the formulation must be optimized for required release profile keeping the total
amount of drug release in mind.
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Complexation of basic drugs with carbopol in basic media is not a universal
phenomenon. Complexation depends on following factors [37]:
i. Shielding of basic groups in the drug molecule. If basic groups of the drug molecule are
shielded by non-ionizing functional groups, then it will reduce the chances for
complexation.
ii. pKa of the drug molecule. Weakly basic drugs undergo complexation to less extent
compared to strongly basic drugs. For example, Verapamil Hydrochloride has pKa of 9.04
and Papaverine Hydrochloride has pKa of 6.8. In comparision, Verapamil Hydrochlorde
undergoes complexation to high extent compared to Papaverine Hydrochloride.
iii. pH of the media and microenvironment must support the complexation. For effective
complexation, the drug and carbopol must be completely ionized. Extent of ionization of
drugs depends on the pH of the medium. Most of the basic drugs exist in completely
ionized state in acidic pH. However carbopol remains unionized in acidic pH. Maximum
swelling and ionization of carbopol resins is reported to occur in pH 5 to 9. Thus, for
formation of drug-carbopol complex, the drug must be in completely ionized state in the
pH values 5 to 9. At these conditions, the swelling of carbopol resin is maximum thus
exposing ionized carboxylic acid groups for complexation with drug molecules. For
example, Propranolol hydrochloride is a basic drug with pKa of 9.5. At acidic pH
proproanolol is completely ionized. At pH 4.5 carbopol starts to ionize and complex with
the ionized drug. At pH 7.5, 97% of carbopol is ionized and 99% of propranolol is ionized.
Thus, the Propranolol – Carbopol complex formation is high in intestinal pH rater than
gastric pH.
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iv. Orientation and spatial arrangement of carboxylic acid groups in hydrated polymer can
influence the extent of complexation. For example, carbopol 934, 940 and 941 have similar
carboxylic acid content. However amount of polymer required for the formation of
saturated drug-polymer complex is significantly different. This implies orientation of
carboxylic acid groups influence the extent of complexation. Orientation of carboxylic acid
groups in hydrated polymer depends on the extent of cross linking. Carbopol grades with
high degree of cross linking don’t “open up” upon hydration as the cross links constrain the
uncoiling of the polymer chains. Thus, higher the cross linking less the chances for
complexation.

1.3.2.5. Bioadhesion characteristics and drug release
Carbopol is an excellent bioadhesive. Bioadhesive nature of carbopol helps to increase
the bioavailability of the drugs [38]. When incorporated in tablets, carbopol increases the gastro
intestinal transit time. Increase in gastric intestinal time improves drug absorption by keeping the
tablet in regions of gastro intestinal tract where the drug absorption is high. Use of carbopol as
bioadhesive to sustain the gastric transit time and improve the efficiency of controlled release
systems is one of the extensively studied topics [38-71].
Y. Capan et al [72] showed that sustained release acetaminophen tablets containing
carbopol 934P as release controlling polymer provided more uniform excretion rate than
conventional controlled release tablets containing cellulose polymers as release controlling
polymer. A similar enhancement in bioavailability was observed by K. Ciftci [73] with lithium
carbonate, a sparingly soluble drug and using carbopol 934P as sustained release matrix. Hence,
it appears that enhancement in bioavailability is not a drug specific phenomenon however more
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general and can be attributed to carbopol’s ability to increase the gastro intestinal transit time. In
a following paper, to illustrate the effect of tablet excipients on the improvement of
bioavailability with carbopol tablets, K. Ciftci [73] et al compared formulations containing water
insoluble fillers (Dibasic calcium phosphate, mirocystalline cellulose) and water soluble fillers
(lactose and dextrates). Formulations containing water insoluble fillers showed poor
bioavailability than conventional formulations containing cellulose polymers while formulations
containing water soluble fillers showed similar bioavailability compared to conventional
formulation. However, in formulations containing water soluble fillers, peak height of urinary
excretion curve was low and the time required to reach peak height is longer indicating the fact
that side effects of the drug may be low with carbopol formulations containing water soluble
fillers. This finding implies that enhancement in performance of drug delivery system can be
observed not only by increase in drug bioavailability with carbopol based polymeric system but
also decrease in side effects of the drugs. These effects are related to other excipients in the
formulation. Thus, in carbopol based tablet formulation the excipients must be selected not only
to achieve an optimum drug release profile but also to maximize therapeutic potential or to
minimize the side effects of the drug.
In vitro dissolution test can serve as an indicator for extent of urinary excretion of drug
from carbopol based sustained release tablets. Perez Marcos [30] et al developed a correlation
between in vitro dissolution and urinary excretion of atenolol tablets containing carbopol 934P as
release controlling polymer.
Bioadhesive property of carbopol makes it suitable excipient in buccoadhesive tablet
formulations [41, 42, 56, 57, 59, 60, 74-81], vaginal formulations [48, 49, 71, 82-84], ocular
formulations [64, 66, 85, 86]. In general, carbopol is blended with other controlled release
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polymer to optimize the drug release profiles. For, although carbopol is a good sustained release
polymer, the gel strength of carbopol is too strong to release drugs with poor solubility.
Therefore, combination of carbopol and other soluble linear cellulosic polymers are used in
buccoahesive formulations.

1.3.2.6. Release kinetics
As discussed earlier, peppas model explain the release mechanism involved in the drug
release. The release exponent “n” in peppas equation, based on the geometry of the device, can
be used to identify the release mechanism. Peppas equation can explain drug delivery systems
with three different geometries i.e., slab, sphere and cylinder. Tablets prepared with flat faced
punches can be considered as slabs. In systems with slab geometry, n=0.5 indicates fickian
diffusion, 0.5<n<1 indicates non-fickian (anomalous) transport, n=1 indicates case II transport
(zero order drug release/time independent), n>1 indicates super case II transport. In non-fickian
type diffusion, rapid release rate is observed in the first phase of the dissolution then the release
rate tails of with time. Combination of diffusion and polymer swelling can cause this type of
anomalous transport. The release exponent values may differ based on type of carbopol used in
the formulation, pH of the dissolution media, drug solubility etc. This implies the release
mechanism is function of multiple factors and drug specific. Generally drug release from
carbopol follows non-fickian release kinetics. However, drug solubility, pH of the dissolution
media, ionic characteristics of the drug and other excipients in the formulations can significantly
influence the drug release kinetics of carbopol matrix [37, 70, 87-93].
For example, poorly soluble theophylline was formulated in sustained release tablet
formulation using carbopol 934P, the release exponent of the formulation in SGF was 0.73 and
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in SIF it was 0.93. This implies, swelling was more predominant mechanism of drug release in
SIF compared to SGF.

1.3.2.7. Excipients in controlled release formulations
Excipients used in the formulations containing carbopol as release controlling matrix can
have significant impact on controlled release property of the matrix [23, 30, 94]. Carbopol is
compatible with most of the commonly used excipients such as anhydrous lactose, hydrated
lactose, dicalcium phosphate, talc, magnesium stearate and starch. Freely water soluble
excipients such as sugars must be avoided. For, upon dissolution the osmotic pressure created by
sugars can break the carbopol matrix. Lactose was a better excipient compared to
microcrystalline cellulose and starch. Microcrystalline cellulose can absorb lot of water into the
tablet effectively ruining carbopol’s ability to retard the water uptake. Thus, formulations
containing microcrystalline cellulose will require more carbopol compared to formulations
containing dicalcium phosphate or lactose. This will increase overall cost of the formulation.
Y. Capan et al [95] compared the use of dibasic calcium phosphate, microcrystalline
cellulose, lactose and dextrates as fillers in sustained release formulation of lithium carbonate.
Tested for their controlled release properties, formulations showed no significant difference in
their prolongation of drug release. However, a significant difference is observed between water
soluble fillers and water insoluble fillers in the urinary excretion of the drug. Formulations
containing water insoluble fillers (dicalcium phosphate, micro crystalline cellulose) showed 8%
less in average total drug excretion compared to formulations containing water soluble fillers
(lactose and dextrates). This implies that invitro differences in the release profile from carbopol
matrix are not an indicator of the biological performance of the formulations.
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Dicalcium phosphate, water insoluble filler, can prolong the dissolution times of carbopol
matrix compared to other water insoluble and soluble fillers. This is attributed to its aqueous
solubility and inability to absorb water unlike micro crystalline cellulose. It noteworthy to
mention that carbopol matrix doesn’t dissolve or disintegrate upon ingestion. They
“deaggregate” and become individual gel micro particles then eliminated from the body. Before
being eliminated, the individual gel particles can control the drug release. Thus, unlike cellulose
ethers, carbopol based system can control the drug release not only when it was in intact shape
but also after deaggregation into gel particles.
Sustained release carbopol tablets containing starch as filler had poor sustained release
properties. Starch is water swellable thus tablet swelling is extremely high resulting in tablet
disintegration.
Carbopol can be processed with other excipients to prepare co-processed excipients [9698]. Such co-processed excipients were found to have superior bioadhesive and controlled
release properties. In spite of research based evidence on advantages of preparing novel coprocessed excipient, no commercial product is available.

1.3.2.8. Modifying release profiles in carbopol matrix
Drug release rate from carbopol matrix can be modified by selection of appropriate
polymer grade and co-excipient in the formulation. Appropriate carbopol grade must be selected
based on the drug solubility and requirement on duration of drug release.
Slow drug release kinetics can be achieved with carbopol 971P or carbopol 934P. In
general, increasing the polymer concentration reduces the drug release. The effect of carbopol
concentration on the drug release depends on the filler used in the formulation. Non-swellable,
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insoluble filler like dicalcium phosphate can prolong the dissolution time. Non-swellable, water
soluble filler like lactose can provide shorter dissolution time. Thus, fine tuning of dissolution
rate can be achieved by selection of appropriate filler or by combining fillers in the formulation.

1.3.2.9. Extrusion spheronization
As described earlier, water is a good plasticizer for carbopol. Glass transition temperature
of carbopol reduces below room temperature when carbopol comes in contact with water. This
makes carbopol based formulations very water sensitive. In extrusion spheronization process, a
wet mass is made using aqueous fluids (water or binder solution) and extruded then spheronized.
In general extrusion spheronization formulations use 30 to 40% of water as wetting fluid for
preparing wet mass. However, if the formulation contains carbopol, then use of water as wetting
fluid is impossible. In such cases, salt solutions can be used as wetting fluids [99].. Salt solutions
reduce tackiness of carbopol. Salt concentration in the solution must be optimized to minimize
the tackiness. Calcium chloride salt solution is commonly used as wetting fluid for formulations
containing carbopol. Calcium chloride concentration is salt of choice as formulations prepared
using calcium chloride salt solution yield pellets with superior roundness and smoothness.
Caclium chloride reduces the tackiness by complexing with ionized carboxylic acid groups.
Calcium ions are bivalent cations and it can complex with two carboxylic acid anions. This
complex nullifies the tackiness of carbopol.
Few studies report use of carbopol in melt extrusion formulations [46, 100]. However, in
melt extrusion formulation carbopol is generally used with other excipients in small quantities to
improve either bioadhesivness of the formulations or to improve the efficiency of the controlled
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release polymer. Carbopol has versatility to be processed in melt extrusion formulations. In
future, novel carbopol based formulations can be developed using melt extrusion technique.
It is our objective to find a method that can improve the usage of carbopol in
pharmaceutical industry. Once if such method is identified, it was also our interest to develop
controlled release matrix formulations using carbopol as release controlling polymer.
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Chapter 2: Evaluation of Granular Characteristics of Carbopol-Wax Blend

2.1. INTRODUCTION
In situ hot melt granulation technology [101] is one of the quickest and simplest
techniques available to prepare sustained release matrix granules. In this technique a waxy
material is used as binder. It is uniformly blended with the drug, polymer and filler before
granulation. During granulation, temperature of the granulator is raised above the melting point
of the wax. Upon melting waxes form a viscous, sticky solution in the granulator to which the
powder particles in the blend adhere and form agglomerate. Owing to the high shear mixing
action in the granulator, the agglomerate is broken into smaller granules. Thus, the granule
formation, breaking and size growth happen simultaneously as the waxy binder melts. Thus, this
process is difficult to model. However, there are many process and formulation variables that can
influence the physical properties of granules obtained. The physical property of granules is
influenced by particle size of the waxy binder, jacket temperature, mixing speed, binder
concentration, granulator load etc.
Carbopol is cross linked poly acrylic acid, commercially available as many grades based
on its degree of crosslinking. Although there are reports on use of Carbopol in preparation of
hydrophilic matrix systems for oral controlled drug delivery, there are many process difficulties
in handling this polymer in industrial setting. Carbopol is commercially available as fine powder
with particles containing mean diameter of 0.2 microns. Owing to its fine particulate nature and
static charge development it generally forms aggregates and mean diameter of these aggregates
is 8 to 15 microns. Carbopol does not flow well because of its fine particulate nature, low density
and static charge development. Carbopol is very sticky and it sticks with any kind of surface.
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Carbopol is also available in granular grades that have bigger mean particle diameter, faster flow.
However, there are different problems with granular carbopol grades. They are: (i) Less
efficency i.e., Efficiency of carbopol to control the drug release is higher when it is used as fine
particles as fine particles can form more intact gel structure. (ii) Use of granular grade does not
solve stickiness problem.
Hot melt granulation of carbopol with waxes can improve its flow characteristics and
reduce the stickiness of carbopol. Since hot melt granulation is an in situ granulation technique,
the powder grade of carbpol can be used thus maximum efficiency of the polymer to control the
drug release can be attained. In this section, the development of hot melt granulation technique
for preparing carbopol granules with Gelucire 50/13 is presented. Gelucire 50/13 is blend of poly
ethylene glycol esters of long chain fatty acids and available as waxy solid. Based on the
literature on in situ hot melt granulation, it was hypothesized that process conditions significantly
influence the physical properties of granules. It was our interest to evaluate the effect of jacket
temperature, mixing speed and massing time on the physical characteristics of the granules. This
will aid in the development of robust granulation technique for preparing carbopol granules
using a waxy binder.

2.2. MATERIALS AND METHODS

2.2.1. Materials
Our primary materials in this study were obtained from commercial sources. They were
Carbopol 971P (Noveon, Cleveland, OH), Gelucire 50/13 (Gattefosse, Paramus, NJ).
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2.2.2. Methods

2.2.2.1. Preparation of carbopol-wax blend
Carbopol-wax granules were prepared using in situ hot melt granulation. Sixteen batches
were prepared using different process conditions. Process conditions for preparing the batches
are given in Table 2.1. Batch size for all batches was 300 gms. Pre-weighed quantities of
carbopol 971P and the waxy binder were added to the Robot Coupe® (Jackson, MS) high shear
granulator. Granulator blade was operated in forward mode for mixing the contents prior to
granulation. Mixing was done at 1500 rpm blade speed for 2 minutes. Following mixing, a
circulating water bath was attached to granulator. Temperature of water bath was set according
to the conditions required for each batch. Temperature of water jacket of the granulator was
maintained constant throughout granulation as per conditions required for each batch.
Temperature of water bath was monitored using an external digital thermometer by placing the
temperature probe of the thermometer in the sleeve in the jacket. Granulation speed and time
were also set according to the conditions required for each batch. Granulation was done for
specified time as per specifications for each batch. After granulation, the granules were allowed
to cool to room temperature by spreading them on metal trays.

2.2.2.2. Bulk density evaluation
Bulk density of the granules was evaluated using a 50 ml measuring cylinder and a
balance. Initially the weight of the measuring cylinder was tarred. Then, the granules were
poured into the measuring cylinder till the fill volume was 40 ml using a funnel. Then the weight
of the measuring cylinder with granules was taken. This gives the weight of the granules.
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Table 2.1. Process conditions used for preparing carbopol–wax blends

Batch code

Granulation
temperature (oC)

Mixing speed
(RPM)

Mixing time (Min)

B-1
B-2
B-3
B-4
B-5
B-6
B-7
B-8
B-9
B - 10
B - 11
B - 12
B - 13
B - 14
B - 15
B - 16

60
60
60
60
65
65
65
65
70
70
70
70
75
75
75
75

1000
1000
2000
2000
1000
1000
2000
2000
1000
1000
2000
2000
1000
1000
2000
2000

1.5
2
1.5
2
1.5
2
1.5
2
1.5
2
1.5
2
1.5
2
1.5
2
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Bulk density of the granules was calculated using Eq. 2.1 and the bulk density of the
formulations is presented in Table 2.2.

Bulk density = Weight of granules/Volume of granules

(Eq 2.1)

2.2.2.3. Granule size evaluation
The particle size and size distribution of each material in the formulation were
determined by the Gilsonic Autosiever (Gilson Company, Inc., Worthington, OH). A series of
sieves with varying mesh size number ranging from 20 to 200 were used in this study. Prior to
the experiment, each sieve was weighed and the initial weight was recorded. Approximately ten
grams of sample were then placed on the top sieve (20 mesh), which was closed by rubber gasket
and spacer. Stack of sieves was then placed onto the shaker and tightened. The stack was
mechanically shaken for a total time of 7 minutes. This total time was divided into 3 parts, time
A, B and C. Time A (60 seconds) was the time required to increase the speed from zero speed to
the predetermined shaking speed, whereas time B, which was set for 5 minutes, was the time
maintained at the maximum amplitude. Time C (60 seconds) was the time required for the
decrease of speed from the maximum amplitude to zero speed.
Once the cycle is completed, the lock was loosened and the stack of sieves was removed
from the shaker. The final weight of each sieve and the retained sample on each sieve and the
sieve was weighed again together and the weight was recorded and the percentage of material
retained on each sieve was calculated. Sieve shaker used in this study uses both ultra sonic
vibrations and mechanical agitation to segregate granules according to their size. Use of ultra
sonic sound for granule size separation minimizes destruction of granules during the test.
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Table 2.2. Physical characteristics of carbopol–wax blends

Batch
code

Bulk
density*
(gms/ml)

Coarse

Medium

Fine

Dynamic
flow rate*
(gms/sec)

B–1

0.276±0.02

4.34±2.11

19.75±1.79

75.91±0.28

8.14±0.51

B–2

0.376±0.05

8.81±1.23

28.50±0.91

62.69±2.39

13.60±0.41

B–3

0.315±0.02

6.97±1.50

18.72±1.55

74.32±1.56

16.15±0.59

B–4

0.326±0.05

26.68±0.82

44.42±0.59

28.89±1.13

13.26±0.98

B–5

0.313±0.03

2.95±0.35

18.14±1.25

78.91±0.53

16.62±0.52

B–6

0.414±0.03

13.06±2.61

32.13±2.85

54.82±2.75

19.64±0.59

B–7

0.380±0.02

6.37±2.09

22.61±1.82

71.03±0.40

20.35±1.49

B–8

0.374±0.04

54.59±2.96

37.19±2.09

8.23±2.77

12.43±0.59

B–9

0.442±0.04

11.24±0.14

35.15±0.51

53.61±1.60

14.90±0.94

B – 10

0.429±0.02

46.61±1.33

44.02±1.10

9.37±2.71

13.42±0.67

B – 11

0.394±0.06

32.99±1.68

45.43±1.22

21.58±2.84

14.11±0.47

B – 13

0.511±0.05

15.16±0.23

36.14±0.10

48.70±2.68

23.40±1.17

B – 14

0.429±0.09

61.39±1.83

33.58±0.49

5.03±2.59

13.29±0.48

Granule size distribution (%)*

*indicates values presented in the table are average of three measurements. Average values are
presented with standard deviation of three measurements.
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Based on the retaining of the granules, they were divided into three categories; (i) Coarse
granules (percent weight of granules retained on no. 30 sieve), (ii) Medium size granules
(percent weight of granules that pass through no. 30 sieve and retained on no. 60 sieve, (iii) Fine
granules (percent weight of granules that pass through no. 60 sieve). Percent weight of coarse,
medium size and fine granules is presented in Table 2.2.

2.2.2.4. Dynamic flow rate evaluation
Dynamic flow of the material was determined using a Hanson Flowdex (Hanson
Research Corporation, Chatsworth, CA). The device consists of a metal cylinder attached to a
metal plate with an orifice at the bottom. This orifice was closed or opened by the movable stage
attached to the bottom of the plate. Material was filled into the cylinder with the orifice closed.
Approximately three fourth of cylinder was filled with the material. Once filled, the movable
stage blocking the orifice was removed from the bottom of the plate and the material was
allowed to flow through the orifice onto a balance, which was connected to a computer. The
dynamic weight change of material that flows through the orifice and time in millisecond were
recorded electronically using Software WinWedge® (TAL Technologies, Inc., Philadelphia, PA).
The data obtained was plotted as the weight of the material versus time. The flow rate was then
determined as the slope of the linear regression of the plot. Dynamic flow rate of all formulations
is presented in Table 2.2.
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2.3. RESULTS AND DISCUSSION

2.3.1. Study design
Objective of the study was to evaluate the effect of mixing speed and massing time of
granulation at different jacket temperatures. Asymmetrical factorial design (41 X 22) with four
different jacket temperatures and two levels (low, high) of mixing speed and massing time was
used in this study.

2.3.2. Bulk density
Effect of mixing speed and massing time on bulk density of the granules at different
jacket temperature is depicted in Figure 2.1. At 60oC jacket temperature and 1000 rpm mixing
speed, increasing the massing time to high level increased the bulk density of the granules by
36.14%. However, at 60oC jacket temperature and 1000 rpm mixing speed, increasing the
massing time to high level increased the bulk density by 3.42% and this increase is statistically
insignificant (P>0.05). This implies that there is a limit of densification achieved at higher speeds
and this limit is reached at low massing time. This could be attributed to the high shear force
created at high mixing speed. At higher shear force, the size growth is faster compared to lower
speeds. However, the granule size increases with no significant increase in density of the
granules. This could be due to the formation of rubbery granules at higher speed. At 65oC jacket
temperature and 1000 rpm mixing speed, increasing the massing time to high level increased the
bulk density of the granules by 32.48%. This is less compared to the change in bulk density
observed at 60oC in same mixing conditions. At 65oC jacket temperature and 2000 rpm mixing
speed, increasing the massing time decreased the bulk density by 1.45%.
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Figure 2.1. Effect of process conditions on bulk densities of formulations†
† Each bar represents average of three measurements. Standard deviation of three measurements
is presented as error bars.
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Although this change is statistically insignificant (P>0.05), it implies formation of
rubbery granules at higher speed. Results indicate formation of rubbery is dependent on the
mixing speed and temperature. This is further supported by granules prepared at 70oC and 75oC.
At 70oC jacket temperature and 1000 rpm mixing speed, increase in bulk density was 20.69%
(lower compared to similar conditions at 60oC and 65oC). At 75oC jacket temperature and 1000
rpm mixing speed, increase in bulk density was 15.01%. This shows that formation of rubbery
granules is dependent on the jacket temperature.
At 70oC jacket temperature and 2000 rpm mixing speed, increasing the granulation time
resulted in formation of rubbery mass. And, at 75oC jacket temperature and 2000 rpm mixing
speed, rubbery mass was formed at low and high massing times. This clearly shows formation of
rubbery granules/mass is dependent on jacket temperature and mixing speed. Based on jacket
temperature and mixing speed settings, the massing time must be optimized to get granules of
desired characteristics. For example, at high jacket temperature and high mixing speed, the
massing time must be low to obtain discrete, free flowing granules.

2.3.3. Granule size distribution
Granule size distribution was non-normally distributed in most of the batches. Thus,
geometric mean diameter could not be used for identifying the effect of process conditions on
granule size growth. Since the size distribution was analyzed using sieves, three sieve cuts have
been defined: coarse, moderate and fine. Granules retained on no. 30 sieve were considered
coarse, granules that pass no. 30 sieve and retain on no. 60 sieve were considered acceptable and
granules that pass through no. 60 sieve were considered fine. Granule size growth in insitu hot
melt granulation is a complex process. It depends on particle size and size distribution of the

45

components of the blend and melting point of the wax, interaction between wax and other
excipients etc.

2.3.3.1. Coarse granules
Effect of temperature and process conditions on the amount of coarse granules is depicted
in Figure 2.2. At 60oC, when blade speed was 1000 rpm and the granulation time was increased
from low to high, there was 102.98% increase in the amount of coarse granules. However, at
60oC, when the blade speed was 2000 rpm and the granulation time was increased from low to
high, there was 282.90% increase in the amount of coarse granules. This indicates that the size
growth of the granules at a given jacket temperature is dependent on both mixing speed and
massing time. The rate of size growth is faster at higher mixing speeds.
A similar trend was observed at 65oC jacket temperature, however, the magnitude of the
size growth was higher than one observed at 60oC. At 60oC jacket temperature and 1000 rpm
blade speed, when the granulation time was increased from low to high, there was 342.69%
increase in the amount of coarse granules. At 65oC jacket temperature and 1000 rpm blade speed,
when granulation time was increased from low to high there was 757.30% increase in the amount
of coarse granules. This indicates that the extent of coarse granules formed is dependent on
mixing speed, massing time and jacket temperature. There is a significant interaction exist
among these variables. Effect of mixing speed and mixing time on the extent of coarse granules
formed will be higher at high jacket temperature. This can be attributed to the faster melting of
wax at higher temperature.
Similar trend was observed with 70oC and 75oC jacket temperatures with few exceptions.
At 70oC, when mixing speed was 2000 rpm, increase in massing time turned the blend rubbery.
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Figure 2.2. Effect of process conditions on the amount of coarse granules†
† Each bar represents average of three measurements. Standard deviation of three measurements
is presented as error bars.
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This also implies that there is an interaction between Gelucire and carbopol 971P and this
interaction results in formation of rubbery product. Formation of rubbery product in granulation
is hastened by jacket temperature and mixing speed.

2.3.3.2. Medium size granules
Effect of temperature and process conditions on the amount of medium size granules is
depicted in Figure 2.3. At 60oC jacket temperature and 1000 rpm mixing speed, increasing the
massing time from low to high increased the amount of acceptable granules by 44.30%.
However, at 60oC jacket temperature and 1000 rpm mixing speed, increasing the massing time
from low to high increased the amount of acceptable granules by 137.35%. This indicates that
formation of acceptable size granules depends on both processing speed and time. High mixing
speed and longer mixing time at low jacket temperature yield more amounts of medium size
granules.
At 65oC jacket temperature and 1000 rpm mixing speed, increasing the massing time
from low to high increased the amount of medium size granules by 77.08%. This is higher
compared to similar processing conditions at 60oC. This implies at 1000 rpm, increasing jacket
temperature and mixing time will yield higher amount of medium size granules. However, the
trend was different at 2000 rpm. At 2000 rpm, increasing massing time increased the amount of
medium size granules in the blend by 64.51%. This is significantly lower compared to similar
conditions at 60oC where 137.35% increase was observed. At 70oC and 1000 rpm mixing speed,
amount of medium size granules increased by 25.23%. However, at 75oC and 1000 rpm
processing speed, amount of acceptable granules decreased by 7.08%.
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Figure 2.3. Effect of process conditions on the amount of medium size granules†
† Each bar represents average of three measurements. Standard deviation of three measurements
is presented as error bars.
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This implies: (i) size growth does not occur uniformly at all jacket temperatures, (ii)
mixing speed and massing time have significant interaction with jacket temperature in
determining the formation of amount of medium size granules.

2.3.3.3. Fine granules
Amount of fine granules is associated with the amount of coarse and acceptable granules
formed and the amount of size reduction during the granulation. For, during in situ hot melt
granulation, size growth and reduction take place simultaneously. Based on the processing
conditions extent of size growth and reduction will differ.
Effect of temperature and process conditions on the amount of fine granules is depicted in
Figure 2.4. At 60oC jacket temperature and 1000 rpm mixing speed, increasing the massing time
to high level decreased the amount of fine granules by 17.41%. However, at 60oC jacket
temperature and implies that effect of jacket temperature on amount of fine granules is
augmented by mixing speed. Aforementioned interpretations are supported by amount of fine
granules formed at 70oC and 75oC at 1000 rpm mixing speed when mixing time was increased.
At 1000 rpm, when mixing time was increased, while amount of fine granules decreased by
82.52% at 70oC jacket temperature, amount of fine granules decreased by 89.67% at 75oC.
Summarily, (i) amount of coarse, acceptable, fine granules formed is dependent on the
jacket temperature, (ii) significant interaction exist between jacket temperature, mixing speed
and mixing time. Generally, size growth is faster at higher temperatures and higher mixing
speeds. And, size reduction was not observed at higher mixing speeds, (iii) at 70oC and 75oC
jacket temperatures, the granulation process becomes sensitive to mixing speed and time.
Increasing mixing time at 70oC and increasing mixing speed at 75oC will form rubbery mass.
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Figure 2.4. Effect of process conditions on the amount of fine granules†
† Each bar represents average of three measurements. Standard deviation of three measurements
is presented as error bars.
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2.3.4. Flow rate
Flow rate of granules depends on granule size, size distribution and density of the
granules. Effect of process conditions on the flow rate of granules is depicted in Figure 2.5. At
60oC jacket temperature and 1000 rpm mixing speed, increase in massing time to high level
increased the flow rate by 67.25%. However, at 60oC jacket temperature and 2000 rpm mixing
speed, increase in massing time to high level decreased the flow rate by 18.06%. This could be
attributed to the density of the granules. Since rubbery and low density granules are formed
faster at higher speed, flow rate and granular density could be related. A similar trend was
observed at 65oC jacket temperature. At 65oC jacket temperature and 1000 rpm mixing speed,
increase in massing time to high level increased the flow rate by 18.12%, which is less compared
to the increase observed in same conditions at 60oC. At 65oC jacket temperature and 2000 rpm
mixing speed, the flow rate decreased by 38.85%. Batch prepared at 75oC jacket temperature
with low mixing speed and low massing time had maximum flow rate (23.38 ± 1.16 gms/sec).
This formulation had maximum density among all formulations (0.51 ± 0.02). This implies that
flow rate and density are related and formation of low density, rubbery granules will result in
reduction in flow rate of granules.

2.4. CONCLUSIONS
Free flowing carbopol granules can be prepared using hot melt granulation process.
Gelucire 50/13 can be used as binder for granulating carbopol in hot melt granulation process.
Physical properties of carbopol – wax granules were dependent on the process conditions used to
prepare them in high shear granulator. Effect of mixing speed and mixing time on the physical
properties of granules was dependent on the granulation temperature. Increase in granulation

52

30

Flow rate (g/sec)

25

1000 RPM@1.5 min

1000 RPM@2 Min

2000 RPM@1.5 Min

2000 RPM@2 Min

20
15
10
5
0
60

65

70

75

Temperature (Cel)

Figure 2.5. Effect of process conditions on the dynamic flow rate of the granules†
† Each bar represents average of three measurements. Standard deviation of three measurements
is presented as error bars.
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temperature turns the granulation process sensitive to mixing speed and mixing time. Free
flowing, discrete carbopol–wax granules can be prepared in various process conditions.
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Chapter 3: Formulation Development of Propranolol Hydrochloride

3.1. INTRODUCTION
Propranolol hydrochloride is a β-adrenergic blocking agent, i.e., a competitive inhibitor
of the effects of catecholamines at β-adrenergic receptor sites. It is widely used in therapeutics
for its antihypertensive, antiangorous and antiarrhythmic properties. Furthermore, it has a short
elimination half-life of 3 h, which makes it a suitable candidate to be delivered at a controlled
rate.
Objective of this work is to develop sustained release matrix tablets of propranolol
hydrochloride using carbopol – wax blends and to optimize the invitro drug release profiles
according to USP criteria. The matrix tablets contained five components. They are
i. Therapeutic agent: propranolol hydrochloride.
ii. Release controlling polymer: carbopol 971P or carbopol 974P.
iii. Binder: glyceryl mono stearate or gelucire 50/13.
iv. Filler: dicalcium phosphate or lactose monohydrate.
v. pH modifiers: sodium carbonate and glycine.
Rationale for selection of aforementioned matrix component is given below.

3.2. SELECTION OF MATRIX COMPONENTS

3.2.1. Selection of release controlling polymer
Carbopols have been reported in the literature for their potential use in oral controlled
release delivery systems. This is because of carbopol’s ability to swell and form viscous gel in
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aqueous environment. Carbopols can absorb lot of water and form gels and these gels are called
hydrogels. When formulated with drugs, the carbopol hydrogels can entrap the drug molecules
and control their release from the delivery system. Carbopols are available in various grades
suitable for pharmaceutical use. Carbopol 971P and Carbopol 974P are the most commonly used
grades used in controlled release oral formulations. Carbopol 971P is less cross linked than
carbopol 974P. The release retardant property of carbopol is directly related to its concentration
in the formulation. In general, drug release rate is inversely proportional to the carbopol
concentration. It is reported that carbopol 971P is more effective than carbopol 974P in oral
controlled release formulations. This is attributed to free uncoiling of polymer chains of carbopol
971P and effective entrapment of drug molecules compared to carbopol 974P.
Carbopol is an anionic polymer. Sixty two percent of the polymer is made up of carboxyl
groups. Hence, it has high potential for interaction with basic drugs. This ionic interaction may
boost carbopol’s controlled release potential i.e., may be effective in low concentrations
compared to cellulose based polymers that have no interaction with basic drugs.
In spite of its efficiency, carbopols are not commonly used in oral controlled delivery
systems. As a result, complete understanding of mechanism of drug release with respect to
dynamic swelling has not been developed. Hence, carbopol has been selected for this study. The
objective of the study is to develop an USP (United States Pharmacopoeia) compliant
formulation of propranolol hydrochloride and to optimize the drug release profiles based on the
mechanism of drug release.
A literature survey showed no supporting literature for formulation development of
propranolol hydrochloride controlled release tablets using carbopol – wax blends. Carbopol is
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one of the most under utilized polymers in the pharmaceutical industry because of following
reasons.
i. Carbopol is commercially available as fluffy powder with average particle diameter of 0.2
microns. Owing to its fine particulate nature, carbopols aggregate forming loose aggregates
with average diameter of 8 to 30 microns. These loose aggregates have poor flow
characteristics because of their low bulk density.
ii. Carbopol is a sticky polymer. It is an excellent bioadhesive and it sticks to any kind of
surface. This stickiness creates process difficulty.
iii. Carbopol turns tacky in presence of water. Water is a good plasticizer for carbopol. When
comes in contact with water, carbopol’s glass transition temperature lowers below room
temperature. Therefore, most commonly used wet granulation process can not be used with
formulations containing carbopol.
Essentially, flow characteristics of carbopol must be improved and stickiness of the material
must be reduced. Manufacturers of carbpol make granular grade of the material using roller
compaction process. This granular grade has better flowability compared to powder grade.
However, if granular grade of the carbopol is used in the formulation, then the efficiency of the
polymer will be low. That is, more amount of polymer will be required to achieve controlled
release properties similar to that of powder grade. Carbopol has unique gelling properties. Each
carbopol particle has potential to form microgel and entrap the drug molecules. In granular
grade, carbopol particles are compacted reducing individual polymer particle’s ability to entrap
the drug molecule. Thus, more polymer is needed to compensate this loss of carbopol’s ability to
control the drug release as polymer microgel. Hot melt granulation technique can solve this
problem. Hot melt granulation is a granulation technique where no water is used for preparing
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granules so polymer sticking is not a problem. Prior to granulation, intimate mixing of carbopol
and the drug is achieved in high shear granulator. This blending provides proximity of carbopol
particles to the drug particles. Therefore, less carbopol concentration is sufficient to control the
drug release compared to using carbopol granules.

3.2.2. Selection of therapeutic agent
Propranolol hydrochloride was selected as model drug for this study for following
reasons.
i. Propranolol Hydrochloride has a high aqueous solubility. As a result, it is difficult to
control its release from matrix tablets. However, if a matrix system is developed and the
properties of system are understood, then it is comparatively easy to develop controlled
drug delivery system for drugs with low solubility.
ii. Propranolol Hydrochlorde is categorized as Class I drug in BCS classification. Class I
drugs have high solubility and high permeability. It has uniform absorption throughout the
gastro intestinal tract. These properties make propranolol hydrochloride as a suitable
candidate for oral controlled release system.
iii. Propranolol Hydrochloride is a basic drug (pKa = 9.5) and carbopol is an acidic polymer.
At intestinal pH, 7.2, 99% of the drug exists in ionized form. At intestinal pH, carboxylic
groups of carbopol are ionized and possess negative charges. Hence, there is potential
interaction between positively charged amino groups of propranolol and negatively charged
carboxylic acid groups. This ionic interaction could retard the drug release. Thus it is of
interest to develop a delivery system which can release the drug completely, complying
with USP standards.
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3.2.3. Selection of pharmaceutical excipients

3.2.3.1. Selection of binder
In this study, besides developing a controlled drug delivery system for propranolol
hydrochloride, the effect of two binders namely Glyeryl Mono Stearate and Gelucire 50/13 on
the granular properties is investigated.
Binder for the formulation development was selected based on favorable granulation
characteristics. The evaluation criteria for granules are predefined and evaluated for formulations
containing carbopol (10%) with binder (10%) and filler (80%). These formulations contained no
drug as the interest was to develop general conclusions from the study rather than developing
drug specific conclusions. The criteria for evaluation are
i. Dynamic flow rate of the formulation must be more than 25 gms/ second.
ii. Hardness of the tablets prepared from formulations using ¼” punches must be at least 4 kps
at low (0.5 mT) and high (1 mT) compression forces.
Two binders evaluated for their potential use in the formulation are Glyceryl Mono Stearate
and Gelucire 50/13. Glyceryl Mono Stearate is a hydrophobic binder. Melting point of Glyceryl
Mono Stearate is 56 to 58oC. It is available as flakes or free flowing powder. For the entire study,
flakes were used. HLB value of Glyceryl Mono Stearate is 1.4 indicating hydrophobicity of the
material. Glyeryl Mono Stearate was selected because of its hydrophobicity and its reported use
in literature for preparing controlled release oral formulations. Being hydrophobic, Glyceryl
mono stearate can retard the water influx into the delivery system. In addition, if used as binder
in hot melt granulation, Glyceryl Mono Stearate can embed the drug particles and form a
dispersion of drug particles in hydrophobic waxy matrix. This will hamper the availability of
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drug particles to dissolution media and indirectly help carbopol’s ability to control the drug
release.
Another waxy binder evaluated in the study was Gelucire 50/13. Gelucire is blend of
Glyceryl esters of fatty acids of poly ethylene glycol. Gelucires are commercially available with
two number suffix, for example 50/13. The first number 50 denotes the melting point of the wax
and the second number 13 denotes the HLB value of the wax. Gelucires are available in various
melting points and HLB values. Gelucires with lower HLB values are hydrophobic and are
recommended for controlled release applications. However, despite of the objective to develop
controlled release product, Gelucire 50/13, a hydrophilic wax, is used. Gelucire 50/13 is selected
to represent hydrophilic waxes as Glyceryl Mono Stearate represents hydrophobic waxes.

3.2.3.2. Selection of fillers
Two fillers are evaluated for their suitability to be used in the formulation. They are
dicalcium Phosphate and Lactose monohydrate. Dicalcium phosphate is water insoluble filler
and has no water swellability. Lactose monohydrate is water soluble filler.
It is reported in literature that use of dicalcium phosphate boosts controlled release
properties of drug delivery system. Being insoluble, dicalcium phosphate resists the water influx
into the delivery system. Controlling water influx is the first step in developing an efficient drug
delivery system. Efficient drug delivery system must not only control the water influx but also
drug efflux. In addition, dicalcium phosphate has excellent flow and compression characteristics
and low cost. Dicalcium phosphate is selected to represent a category of water insoluble, nonswellable fillers.
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Lactose monohydrate represents water soluble, non-swellable filler. Lactose is a natural
disaccharide and prepared from milk. It is one of the most commonly used excipients in
sustained and immediate release formulation. It is water soluble. It has solubility of 1g in 4.63 ml
of water at room temperature.

3.2.3.3. Selection of pH modifiers
Sodium carbonate and glycine were selected as pH modifiers. Sodium carbonate
represents category of strong alkaline salts and glycine represents category of weakly alkaline
salts.
As discussed earlier, carbopol is an anionic polymer with pH dependent gelling
properties. In acidic pH (stomach) carbopol does not gel and in basic pH (intestine) carbopol
forms strong gel. Since it does not gel, carbopol based matrix burst releases drug in acidic media
and as it forms strong gel, carbopol based matrix releases drug incompletely in basic media.
Thus, typically a burst release is observed following slow drug release in standard testing
conditions (first 2 h in pH 1.2 and remaining time in pH 6.8). It was hypothesized that pH
independent carbopol matrix can be developed by incorporating alkaline salts in the formulation.
For comparative purposes, a strong alkaline salt e.g. Sodium carbonate and a weak alkaline salt
e.g. glycine was selected to test this hypothesis. Following changes are expected in the matrix
properties and drug release kinetics (Table 3.1).
i. In acidic media, carbopol is likely to gel in presence of an alkaline salt. Normally, carbopol
does not gel in acidic media and allows acid influx into the tablet. As acid penetrates the
tablet, it reacts with the alkaline salt. This initiates acid-base reaction and result in increase
in micro environment pH. If the increase in the pH of micro environment is high enough,
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Table 3.1. Comparison of changes in gelling and release characteristics

Media

No pH Modifier

With pH modifer

Acid
(pH: 1.2)

No gelling
Burst release

Surface gelling
No Burst release

Basic media
(pH: 6.8)

High gel stength
Incomplete drug release

Low gel stength
Complete drug release
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then carbopol gels and reduce the drug efflux from the tablet. This will control the burst
release.
ii. In basic media, presence of the salt in the tablet further increases micro environment pH.
For example, when the pH of the dissolution media is 6.8 externally, inside the tablet the
pH will be higher than 8 in presence of alkaline salt in the tablet. Carbopol gels have
unique pH dependent strength. Gel strength of carbopol is at peak when the pH of the
media is in the range of 5 to 9. pH values lower than 5 and pH values above 9 will reduce
the gel strength. According to this, pH dependent gel properties, in presence of alkaline
salts, carbopol matrix will de-aggregate in basic media (pH 6.8). This will help the matrix
to achieve complete drug release.
Formulation development of controlled release propranolol hydrochloride tablets was
carried out in two steps.
i. Selection of filler and binder for the formulation development
ii. Development of sustained release formulations of propranolol hydrochloride
a. Effect of alkali salts on the drug release
b. Assessment of release mechanism
c. Optimization of release profiles

3.3. MATERIALS AND METHODS

3.3.1. Materials
Propranolol Hydrochloride, Glyceryl Mono Stearate (GMS) (Stepan, Northfield, IL),
Gelucire 50/13 (Gattefosse, Paramus, NJ), Dicalcium phosphate Dihydrate (Ditab®) (Rhodia,
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Cranbury, NJ), Lactose monohydrate spray dried (Foremost, Baraboo, WI), Carbopol 971P
(Noveon, Cleveland, OH), Carbopol 974P (Noveon, Cleveland, OH), Sodium carbonate
anhydrous (Fisher Chemicals, St. Louis, MO)., Glycine (Fisher Chemicals, St. Louis, MO).

3.3.2. Methods

3.3.2.1. Preparation of granules
Granules for filler evaluation and preparation of sustained release tablets were prepared
using hot melt granulation technique. Ingredients of formulations and composition of the
formulations for selection of fillers are given in Table 3.2 and Table 3.3 respectively. Batch size
of each formulation was 300 gms. Ingredients of the formulations except the waxy binder were
blended in Robot Coupe® high shear granulator for 2 min at 1500 rpm.
A circulating water batch was attached to jacketed walls of the granulator. Enough time
was allowed for the temperature of the granulator to rise to 60oC and the temperature of the
granulator was maintained at 60oC and the blade speed was 1500 rpm for the entire granulation
process. Once the temperature of the granulator reached 60oC, the waxy binder was added to the
granulator and the granulation was carried out for 2 minutes. After 2 minutes, the granulated
mass was passed through # 16 sieve and the obtained granules were allowed to cool to room
temperature. Granules were stored in double zip-lock® bags till compression.

3.3.2.2. Preparation of tablets
Granules, as prepared above, were compressed into tablets using rotary tablet punching
machine. All batches were compressed with only one punch out of 18 punches of the machine.
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Table 3.2. Ingredients of formulations for selection of fillers

Batch code

Wax

Filler

Carbopol

FIL – 1

GMS

Lactose

No

FIL – 2

GMS

Ditab

No

FIL – 3

GMS

Lactose

Yes

FIL – 4

GMS

Ditab

Yes

FIL – 5

Gelucire 50/13

Lactose

No

FIL – 6

Gelucire 50/13

Ditab

No

FIL – 7

Gelucire 50/13

Lactose

Yes

FIL - 8

Gelucire 50/13

Ditab

Yes
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Table 3.3. Composition of formulations for selection of fillers

Batch code

Wax (%)

Filler (%)

Carbopol (%)

FIL – 1

10

90

0

FIL – 2

10

90

0

FIL – 3

10

80

10

FIL – 4

10

80

10

FIL – 5

10

90

0

FIL – 6

10

90

0

FIL – 7

10

80

10

FIL - 8

10

80

10
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Tablet weight of the all formulations was 320 mg and tablets were prepared using 5/16” deepconcave punches. Tablet punching machine was operated with only one punch and remaining
seventeen die cavities of the rotary punching machine were covered with blank dies. Machine
was operated at 20 RPM for preparation of all formulations in the study.

3.3.2.3. Bulk density evaluation
Bulk density of the granules was evaluated using a 50 ml measuring cylinder and a
balance. Initially the weight of the measuring cylinder was tarred. Then, the granules were
poured into the measuring cylinder till the fill volume was 40 ml using a funnel. Then the weight
of the measuring cylinder with granules was taken. This gives the weight of the granules. Bulk
density of the granules was calculated using following formula and the bulk density of
formulations is given in Table 3.4.

Bulk density = Weight of granules/Volume of granules

(Eq. 3.1)

3.3.2.4. Evaluation of dynamic flow rate
Dynamic flow of the material was determined using a Hanson Flowdex® (Hanson
Research Corporation, Chatsworth, CA). The device consists of a metal cylinder attached to a
metal plate with an orifice at the bottom. This orifice was closed or opened by the movable stage
attached to the bottom of the plate. Material was filled into the cylinder with the orifice closed.
Approximately three fourth of cylinder was filled with the material. Orifice was selected based
on final dosage form weight. Granules were to be compressed as 100 mg tablets for evaluation of
compressibility characteristics. Therefore 8 millimeter orifice was selected.
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Table 3.4. Physical characteristics of formulations for filler selection†

Batch code Bulk density (gms/ml)

Flow rate
(gms/sec)

Tablet hardness
at 0.5 mT (kps)

Tablet hardness
at 1 mT (kps)

FIL – 1

0.529±0.02

15.98±0.51

2.32±0.33

2.38±0.16

FIL – 2

0.865±0.04

26.14±0.78

3.35±0.15

3.60±0.11

FIL – 3

0.561±0.02

25.33±0.81

2.98±0.13

3.30±0.11

FIL – 4

1.136±0.02

44.29±1.25

4.97±0.14

5.27±0.69

FIL – 5

0.531±0.02

10.54±0.56

1.98±0.23

2.13±0.08

FIL – 6

0.917±0.05

23.54±0.67

4.23±0.29

4.37±0.32

FIL – 7

0.503±0.03

0.00±0.00

3.97±0.40

4.40±0.60

FIL - 8

1.011±0.03

19.87±0.78

3.47±0.42

3.72±0.52

† indicates values presented in the table are average of three measurements. Average values are
presented with standard deviation of three measurements.
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Once filled, the movable stage blocking the orifice was removed from the bottom of the
plate and the material was allowed to flow through the orifice onto a balance, which was
connected to a computer. The dynamic weight change of material that flows through the orifice
and time in millisecond were recorded electronically using Software WinWedge® (TAL
Technologies, Inc., Philadelphia, PA). The data obtained was plotted as the weight of the
material versus time. The flow rate was then determined as the slope of the linear regression of
the plot and the dynamic flow rate of formulations for filler selection is given in Table 3.4.

3.3.2.5. Evaluation of compressibility
Compressibility of the granules was evaluated by estimating tablet hardness of tablets
prepared from the granules. Granules, as prepared above, were compressed into tablets using
rotary tablet punching machine. Tablet weight of the all formulations was 100 mg and tablets
were prepared using 1/4” flat faced punches. Tablet punching machine was operated with only
one punch and remaining seventeen die cavities of the rotary punching machine were covered
with blank dies. Machine was operated at 20 RPM for compressibility evaluation study. Tablets
were compressed in two compression forces i.e., 0.5 mT and 1 mT. After compression the tablets
were stored in Ziplock® bags for one day before hardness evaluation. Tablet hardness was tested
for randomly selected six tablets for each compression force. Hardness testing was done using
Pharmatest® hardness tester and the hardness of tablets prepared at 0.5 mT and 1 mT
compression force is given in Table 3.4.
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3.3.2.6. Evaluation of in vitro drug release
In vitro drug release characteristics of tablets were assessed using Paddle method (USP
method II). Dissolution test was carried out in two different pH media to simulation gastro
intestinal conditions. First 2 h, the dissolution test was carried out in 750 ml of pH 1.2 acidic
media (0.1 N HCl). Then, 250 ml of 1 N Tribasic sodium phosphate solution was added to
increase the pH of the dissolution media to 6.8. Required quantity of 1 N Sodium hydroxide
solution was used to adjust the pH of the dissolution media if necessary after addition of 250 ml
of 1N tribasic sodium phosphate solution. Thus, dissolution was carried out in 250 ml of 0.1 N
HCl for first 2 h, then 1000 ml of combination media with pH 6.8 for remaining 10 h. Total
length of the dissolution test was 12 h.
Drug release was measured using fiber optic UV probes with 5 mm inserts. Inserts are
fixed at one end of the UV probe and the other end of the UV probe is connected to UV
spectrophotometer with photo diode array detector. One end of the UV probe containing insert
was immersed into the dissolution media during the dissolution study. Insert contains a reflecting
mirror and the UV probe is designed in such a way that presence of insert forms an open
chamber in which the drug solution will flow through during dissolution test. During dissolution
test, at predetermined time intervals, the UV light from UV spectrophotometer is passed through
UV probe. The UV light travels in the UV probe and transmits through the drug solution and
reflected back to the detector by the reflecting surface in the insert. Based on the drug
concentration in the solution contained in the open chamber, there are differences in the incident
light and reflected light. UV absorbance of the drug solution was calculated from the differences
in the intensity of incident light and reflected light. Reference drug absorbance was used to
calculate the drug concentration in the solution. Calculation of drug concentration was based on
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reference drug absorption taken at maximum wavelength of absorption for propranolol
hydrochloride i.e., 278 nm. Volume of the dissolution media at the sampling time, drug loading
were used to calculate the percent drug released. All these calculations were done in Indigo®
software and the results were exported to Microsoft Excel®.

3.3.2.7. Evaluation of mechanism of drug release
The formulations' capacity for hydration (buffer medium uptake) and their extent of
erosion were evaluated gravimetrically. This study was carried out similar to in vitro dissolution
test i.e., for first 2 h the medium uptake was carried out in 0.1 N HCl then in 1000 ml of
combination media containing 750 ml of 0.1 N HCl and 250 ml of 1 N tribasic sodium phosphate
solution. For each time point, two tablets of each formulation were weighed individually and
exposed to dissolution media. The test conditions such as paddle speed and the temperature were
similar to that of dissolution test. At specific time points, tablets were removed from the medium,
patted gently with a tissue paper, weighed, dried at 60 °C until constant weight was achieved.
Percent weight gain (hydration) and % mass loss (erosion) were calculated according to the
equations 3.1 and 3.2 using original, wet, and dry weight values obtained from the testing.

% weight gain =

% erosion =

Wetweight − Dryweight
X 100
Dryweight

Originalweight − remaining (dry ) weight
X 100
Originalweight
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(Eq.3.1)

(Eq.3.2)

3.4. RESULTS AND DISCUSSION

3.4.1. Selection of fillers

3.4.1.1. Bulk density
Statistical analysis of effects of carbopol, type of wax and type of filler is given in Table
3.5. Analysis indicates that change in wax type from Glyceryl Mono Stearate to Gelucire 50/13
significantly reduced the bulk density of the granules obtained in the hot melt granulation.
Changing filler in the formulation from lactose to Ditab significantly increased the bulk density
of the granules. This could be attributed to the higher density of Ditab compared to that of
lactose. Addition of carbopol in the formulations significantly increased the bulk density of the
granules. This implies that carbopol can act as binder and enhance the densification of granules
during hot melt granulation. This results in formation of higher density granules in presence of
carbopol.
No significant interaction was observed between effects of wax and fillers on the granule
bulk density. This implies that effect of wax on the bulk densities of granules remains unchanged
in lactose and Ditab. However, there is significant interaction observed between effects of wax
and presence of carbopol in the formulation. This indicates, when Gelucire 50/13 was used as
waxy binder, the increase in the granule bulk density is marginal. However, when Glyeryl Mono
Stearate was used as waxy binder the increase in the granule bulk density is significant. If bulk
densities of lactose and Ditab are compared, lactose has less density than Ditab. As densities of
pure excipients are significantly different, the granules obtained from them will have
significantly different bulk densities.
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Table 3.5. Statistical analysis of physical characteristics

Effect

Bulk density
(gms/sec)

Flow rate
(gms/sec)

Intercept

0.76*

20.71*

3.41*

3.65*

Wax (GMS - Gelucire)

0.02*

7.22*

0.00

-0.01

Filler (Lactose - Ditab)

-0.23*

-7.75*

-0.60*

-0.59*

Carbopol (Yes-No)

-0.05*

-1.66*

-0.44*

-0.53*

Wax X Filler

0.00

0.47*

-0.16

-0.20

Wax X Carbopol

-0.03*

-5.21*

-0.13

-0.12

Filler X Carbopol

0.05*

1.96*

-0.23

-0.27

* indicates values are significant at P<0.05.
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Tablet hardness Tablet hardness
at 0.4 mT (kps) at 1 mT (kps)

When lactose was used as filler in the formulations, addition of carbopol to the formulation had
no significant influence on the granule bulk density. However, when Ditab was used as filler in
the formulation, addition of carbopol in the formulation significantly increased the granule bulk
density.

3.4.1.2. Dynamic flow rate
Statistical analysis of effect of carbopol, type of wax and type of filler on flow rate is
given in Table 3.5. Statistical analysis indicates that change of wax type from Glyeryl Mono
Stearate to Gelucire 50/13 significantly reduced the flow rate. Changing filler type from lactose
to Ditab significantly increased the flow rate of the granules. Presence of carbopol in the
formulation increased the flow rate significantly. Significant interaction existed between the
effect of wax type and the presence of carbopol in the formulation. This indicates, when no
carbopol was present in the formulation, change in wax type from Glyceryl Mono Stearate to
Gelucire marginally changed the flow rate. However, when carbopol was present in the
formulation, change in the waxy binder from Glyceryl Mono Stearate to Gelucire significantly
reduced the flow rate. This confirms that effect of waxy binder on the granule flow rate is
dependent on the presence of carbopol. Similarly, effect of filler on the flow rate of the granule is
dependent on the presence of carbopol in the formulation.
When lactose is used as filler, addition of carbopol did not significantly increase flow
rate. However, when Ditab was used as filler, addition of carbopol significantly increased the
flow rate. Thus, the effect of carbopol on the granule flow rate is dependent on the type of filler
used in the formulation.
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3.4.1.3. Compressibility
Statistical analysis of the effect of Carbopol, type of wax and type of filler on the tablet
hardness at low compression force (0.4 mT) is given in the Table 3.5. Statistical analysis
indicates that change in the wax type had no significant influence on the tablet hardness at lower
compression force. However, type of filler and presence of carbopol had significant influence on
the tablet hardness. Change of filler from lactose to Ditab significantly increased the tablet
hardness. Similarly, addition of carbopol in the formulation significantly increased the tablet
hardness. Surprisingly, none of the interactions were significant. This implies, the main effects of
individual factors remain unchanged in presence of other factors.
Statistical analysis of the effect of carbopol, type of wax and type of filler on the tablet
hardness at high compression force (1 mT) is given in Table 3.5. Statistical analysis indicates
that the effect of wax type, filler type, presence of carbopol had similar influence on the tablet
hardness (at high compression pressure) as their influence on tablet hardness at low compression
pressure. That is, change of filler to Ditab in the formulation, increased the tablet hardness and
addition of carbopol in the formulation increased the tablet hardness. None of the interactions
among these factors were significant.
It is noteworthy to mention, that the maximum hardness of each formulation was reached
at low compression force and only marginal increase in the tablet hardness was observed when
tablets were prepared at high compression pressure.
In summary, fillers and binders were evaluated for their ability to flow well (at least 25
gms/sec) and compress well (4 kps hardness). Based on the results, Dicalcium phosphate is
selected as filler and Glyceryl Mono Stearate as waxy binder for formulation development.
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3.4.2. Development of controlled release formulation

3.4.2.1. Formulations containing sodium carbonate as release modifer
Ingredients and composition of formulations for product development are presented in
Table 3.6 and Table 3.7 respectively. Formulations PHP 1 to PHP 3 served as controls to
evaluate the effect of pH modifer on the release profiles of formulations containing different
concentrations of carbopol. Formulations PHP 4 to PHP 6 contained 10% sodium carbonate as
release modifier. Comparison of the release profiles among different formulations was made by
comparing the mean values of the drug release at 1 h, 3 h, 6 h and 12 h. These time points were
selected as USP standard for sustained release dosage form of Propanolol Hydrochloride
containing 80 mg of the active drug. USP recommends comparison of drug release at these time
points. PHP 1 and PHP 2 formulations served as controls to estimate the effect of Carbopol on
the drug release. PHP 1 contained all ingredients except carbopol and pH modifer. PHP 2 and
PHP 3 contained all ingredients except pH modifer. Release profiles of PHP 1, PHP 2 and PHP 3
are presented in Figure 3.1. Student t-test comparing the amount of drug released between these
two formulations was found to be significant at 1 h, 3 h, 6 h and 12 h. This implies, addition of
carbopol can significantly reduce the drug release and the effect of carbopol on the drug release
is dependent on the carbopol concentration. That is, formulations contain low levels of carbopol
release drug faster than formulations containing high levels of carbopol. Formulations PHP 4 and
PHP 5 show the effect of 10% of sodium carbonate on the drug release profiles of formulations
containing 10% and 5 % of carbopol respectively.
Comparison of dissolution profiles formulations containing carbopol and carbopol with
sodium carbonate is presented in Figure 3.2.
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Table 3.6. Ingredients of formulations for product development

Batch code

Carbopol type

Wax

pH modifer

Filler

PHP – 1

No carbopol

GMS

No pH modifer

Ditab

PHP – 2

971 P

GMS

No pH modifer

Ditab

PHP - 3

971 P

GMS

No pH modifer

Ditab

PHP - 4

971 P

GMS

PHP – 5

971 P

GMS

PHP – 6

No carbopol

GMS

PHP – 7

971 P

PHP – 8

Sodium
carbonate
Sodium
carbonate
Sodium
carbonate

Ditab

GMS

Glycine

Ditab

971 P

GMS

Glycine

Ditab

PHP – 9

No carbopol

GMS

Glycine

Ditab

PHP – 10

971 P

GMS

No pH modifer

Lactose

PHP – 11

974 P

GMS

No pH modifer

Lactose

PHP – 12

974 P

GMS

No pH modifer

Ditab
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Ditab

Ditab

Table 3.7. Composition of formulations for product development

Batch code

Carbopol (%)

Wax (%)

pH modifer (%)

Filler (%)

PHP – 1

0

10

0

65

PHP – 2

10

10

0

55

PHP - 3

5

10

0

60

PHP - 4

10

10

10

45

PHP – 5

5

10

10

50

PHP – 6

0

10

10

55

PHP – 7

10

10

10

45

PHP – 8

5

10

10

50

PHP – 9

0

10

10

55

PHP – 10

10

10

0

55

PHP – 11

10

10

0

55

PHP – 12

10

10

0

55
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Figure 3.1. Effect of carbopol on drug release†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Figure 3.2. Effect of 10% sodium carbonate on dissolution profiles†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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If formulations PHP 2 and PHP 4 are compared, then the effect of adding 10% sodium carbonate
to formulations containing 10% carbopol will be evident. Student t-test comparison of drug
released at 1 h, 3 h, 6 h and 12 h revealed that the drug release was significantly different in these
formulations at 1 h, 6 h and 12 h. Formulations containing sodium carbonate had less extent of
drug release. This implies, that sodium carbonate can reduce the drug release from matrix tablets
containing carbopol. A similar trend was observed in comparison between formulations PHP 3
and PHP 6. This implies that Sodium carbonate can reduce the drug release from matrix tablets
containing carbopol irrespective of carbopol’s concentration. However, the extent of effect of
sodium carbonate on drug release is dependent on carbopol’s concentration. This implies that
carbopol has more influence on the drug release than the sodium carbonate. Thus, sodium
carbonate must always be used in conjunction with carbopol to effectively control the drug
release. This fact is evident in dissolution profiles of formulation PHP 6. When compared against
PHP 1, PHP 6 had no significant difference in the drug release at all data points. This implies,
having only sodium carbonate in the tablets with no carbopol is an ineffective way of controlling
the drug release. It is noteworthy to mention that addition of sodium carbonate has significantly
reduced the drug release throughout the entire dissolution profile. This is in contrary to the
expected outcome of the presence of sodium carbonate in the tablets. It was expected that when
sodium carbonate is present in the tablet and the tablet is in dissolution media with pH 6.8, then
the microenvironment pH within the tablet will be higher than pH 9. This will degenerate the
matrix and release the drug faster.
However, the results were different than expected. This implies that drug-carbopol
complex formed at basic pH value is predominantly controlling the drug release. Moreover, in
comparison among PHP1, PHP2 and PHP 3, it is evident that formulations containing carbopol
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had incomplete drug release. This implies the formation of carbopol - propranolol hydrochloride
complex results in incomplete drug release.

3.4.2.2. Formulations containing glycine as release modifer
Formulations PHP 7 to PHP 9 contained glycine as release modifier. Comparison of the
release profiles among different formulations were made by comparing the mean values of the
drug release at 1 h, 3 h, 6 h and 12 h. Formulations PHP 7 and PHP 8 shows the effect of 10% of
glycine on the drug release profiles of tablets containing 10% and 5 % of carbopol respectively.
Dissolution profiles of PHP 7 and PHP 8 with their control formulations containing similar
concentration of carbopol are presented in Figure 3.3. If formulations PHP 2 and PHP 7 are
compared, then the effect of adding 10% glycine to formulations containing 10% carbopol will
be evident. Student t-test comparison of drug released at 1 h, 3 h, 6 h and 12 h revealed that the
differences in the drug release were statistically insignificant at all aforementioned time points.
This implies that glycine can not reduce the drug release from matrix tablets containing
carbopol at 10% concentration. A similar trend was observed in comparison between
formulations PHP 3 and PHP 8. This implies that glycine can not reduce the drug release from
matrix tablets containing carbopol and this effect is similar in low (5%) and high (10%) carbopol
concentration. These comparisons illustrate that glycine is an ineffective release modifier at 10%
concentration.
3.4.2.3. Evaluation of mechanism of drug release
Water absorption and erosion profile of formulations containing no carbopol (control), 10%
carbopol, 10% carbopol with 10% sodium carbonate and 10% carbopol with 10% glycine are
presented in Figure 3.4.
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Figure 3.3. Effect of 10% glycine on dissolution profiles†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Figure 3.4. Water absorption profile of formulations
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Formulation containing no carbopol had almost constant amount of water in the tablet
throughout the testing period. This formulation was made with only waxy binder. Literature
reports that formulations made with waxy materials release drug through pore diffusion. Pore
diffusion is concentration driven drug diffusion process in which drug is released through pores
in the matrix. Pore diffusion is not dependent on the water uptake of the matrix. This is evident
from the water absorption profile of tablet prepared with waxy binder.
Formulation containing 10% carbopol had significant increase in water uptake till 8 h
then the increase was marginal. This can be attributed to the presence of carbopol in the tablet.
Carbpol is hydrophilic, swelling polymer. Matrix tablets containing such polymers continue to
absorb dissolution media and this absorption depends on gel layer thickness, geometrical extent
of swelling, solubility of the matrix components. If there is no interaction between drug and
other components of the matrix, then the drug release must chiefly be dependent on the extent of
water uptake of the matrix. Formulation containing 10% carbopol and 10% sodium carbonate
had higher water uptake than formulation containing only carbopol. This could be because of the
osmotic gradient created due to the dissolution of sodium carbonate in the tablet and the
relaxation of polymeric chains due to presence of a salt that can induce ionization of polymeric
chains.
A similar trend in water absorption was observed in formulation containing 10% carbopol
and 10% glycine, although the extent of water absorption was less than that of formulation
containing sodium carbonate.This implies alkalinity of the salt has some relationship with extent
of water absorption i.e., strong alkaline salts can induce the higher water absorption of the
matrix. Thus, based on the effect of water absorption on the drug release, the water absorption of
the matrix system can be modulated by adjusting alkalinity of the salts. Unexpectedly, the extent
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of media absorption at the end of 2 h remained virtually same in all four formulations.
Supposedly, the formulations containing alkaline salts were expected to have less acid uptake as
the matrix is expected to gel due to change in microenvironment pH inside the tablet.
Erosion profiles of aforementioned formulations are given in Figure 3.5. This Figure 3.5
reveals that the extent of erosion of all formulations was similar. This was unexpected.
Formulations containing alkali salts were expected to have higher extent of matrix erosion due to
the expected higher microenvironment pH.
Water absorption and erosion studies reveal two important facts. They are: First, alkali
concentration used in the formulations was insufficient to reduce the acid uptake into the tablets.
Second, alkali concentration used in the formulation was insufficient to induce the matrix erosion
in pH 6.8.
Relationship between the %water uptake and % erosion with %cumulative drug released
respectively is presented in Figure 3.6 and Figure 3.7. Figure 3.6 showing relationship between
% water uptake and %drug released reveals a positive slope in formulations containing carbopol
and carbopol with alkai salts. This implies the drug release is related to % water uptake only less
extent. Figure 3.7 showing relationship between % erosion and % drug released illustrates no
relationship between matrix erosion and drug release. These plots confirm that the drug release is
related to % water uptake to less degree and has no relationship with % erosion. Absence of
matrix erosion can be attributed to incomplete drug release in formulations containing carbopol.
Since the drug release is not significantly dependent on the %water uptake and %
erosion, the main mechanism by which the drug release is controlled is ionic interaction between
drug and carbopol.
Thus, combining these results, to achieve complete drug release from carbopol matrix the
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Figure 3.5. Erosion profiles of formulations
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Figure 3.6. Relationship between water absorption and dissolution profiles
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Figure 3.7. Relationship between erosion and dissolution profiles
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grade of carbopol selected must have less chance to form complex with the drug. For example,
carbopol 974, a grade with higher crosslink density, may be selected. Excipient in the
formulation must support matrix erosion. This will counterbalance the effects of ionic
complexation. All aforementioned formulations contained Ditab as filler. Ditab is water
insoluble. It can be replaced with Lactose Monohydrate, water soluble filler.

3.4.2.4. Formulations with lactose filler
Ditab, the insoluble filler, was replaced with lactose monohydrate to achieve complete
drug release while keeping the acidic drug release in control. Complete drug release can also be
achieved by reducing the polymer concentration in the formulation. However, if the polymer
concentration is reduced the duration of drug release will be shorter and the drug release in acid
will be higher. This is undesirable to develop a formulation that complies with USP standards.
Comparison of dissolution profiles of formulations containing Ditab as filler and lactose
monohydrate as filler is presented in Figure 3.8. The comparison reveals, change in the filler
from Ditab, an insoluble filler, to lactose monohydrate, a soluble filler has increased the drug
release. The amount of drug released at 12 h was 68.43% in lactose monohydrate based
formulations and this is significantly higher compared to 12 h release of 56.35% in Ditab based
formulations with carbopol 971P as release controlling polymer. However, the USP compliant
formulations must have 12 h drug release of not less than 80%. Thus, change in filler type to
filler with higher solubility failed to yield the USP compliant formulation.
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Figure 3.8. Effect of fillers on formulations containing carbopol 971P†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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3.4.2.5. Formulations containing carbopol 974P as release controlling polymer
In the second step, the type of carbopol, release controlling polymer, was changed. In all
aforementioned formulations, carbopol 971 P was used as release controlling polymer. Carbopol
971 P is less crosslinked compared to carbopol 974P. Hydrogels formed from carbopol 971P has
“fishnet” structure while the hydrogels formed from carbopol 974P has “fuzzball” structure.
Polymer chains of hydrogels with “fishnet” structure have more mobility compared to the
hydrogels of “fuzz ball” structure. Free mobility of polymer chains increases the probability of
complexation between ionized polymer and the drug molecule. Thus, polymers with less
crosslinks will impede the drug release to higher extent compared to polymers with high
crosslinks. In formulation containing lactose monohydrate as filler and carbopol 971P as release
controlling polymer the change was made. Carbopol 971P was replaced by carbopol 974P, a
highly crosslinked grade of carbopol. Comparison of release profiles of formulations containing
carbopol 971P and carbopol 974P is given in Figure 3.9. The Figure 3.9 clearly illustrates the
complete drug release was achieved at the end of the dissolution. Comparison between the USP
standards and dissolution profile of formulation containing lactose monohydrate as filler and
carbopol 974P as release controlling polymer is given in Table 3.8.
Although the USP compliant sustained release (SR) formulation was developed by
combining highly cross linked grade of carbopol and soluble filler, it is not clear the final result
is due to change in the carbopol grade or due to the change in the filler solubility.
Thus, one more formulation was prepared using carbopol 974P as release controlling
polymer however using dicalcium phosphate, water insoluble filler, as filler in the formulation. It
was hypothesized that the complete drug release is due to the replacement of carbopol 971P by
carbopol 974P then the change in filler must still a formulation that can release the drug

92

100
90

Cum. % Drug Released

80
70
60
50
40
30

Carbopol 971P+Lactose

20

Carbopol 974P+Lactose

10
0
0

2

4

6
Time (h)

8

10

Figure 3.9. Effect of carbopol grade on dissolution profiles†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Table 3.8. Comparison between optimized formulation and USP specifications

Time

USP requirement
(80 mg SR tablet)

Formulation with 10% 974P
with lactose

1h

Less than 20%

20.21±2.36%

3h

20-45%

40.71±2.84%

6h

45-60%

58.28±2.75%

12 h

Not less than 80%

96.79±3.67%
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completely at the end of 12 h. Otherwise, the complete drug release is attributed to both
solubility of filler and reduction in the extent of complexation between drug and carbopol. The
formulation containing dicalcium phosphate as tablet filler did not yield complete drug release at
the end of 12 h (58.96% drug release at 12 h). Therefore, it is confirmed that complete drug
release is an effect of water solubility of the filler and reduction in the complexation of drug with
carbopol.

3.5. CONCLUSION
Sustained release matrix tablets of propranolol hydrochloride can be developed using
carbopol – wax blends. Mechanistic studies confirmed insignificant relationship between water
absorption profiles and drug release profiles from formulations containing carbopol 971P as
release controlling polymer. Little or no matrix erosion contributed to incomplete drug release
from tablets containing carbopol 971P. Absence of matrix erosion and high degree of
complexation resulted in incomplete drug release in formulations containing carbopol 971P as
release controlling polymer. Sustained release formulation showing USP compliant drug release
profiles was prepared using appropriate carbopol grade (carbopol 974 P) and filler (lactose
monohydrate). Thus, selection of appropriate carbopol grade and soluble filler were pivotal in
developing USP compliant formulation of propranolol hydrochloride.
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Chapter 4: Formulation Development of Glipizide

4.1. INTRODUCTION
Type 2 diabetes is one of the most prevalent diseases in the modern world. Diabetes is
currently the fourth leading cause of death by disease in the United States. Type 2 diabetes
represents 98% of all diabetes among patients older than 45 years of age.
There are two widely accepted hypotheses about origin of type 2 diabetes. First one is
related to insufficient insulin secretion from beta cells. The second hypothesis is related to
insulin resistance in the peripheral tissues. The beta cells initially compensate the normal glucose
metabolism by increasing insulin secretion. However, when the demand for insulin exceeds the
ability of beta cells to compensate, it leads to pancreatic exhaustion.
As first line of defense for diabetes, diet and exercise regimen is recommended to
patients. Upon six weeks course of diet and exercise plan, patients will show improvement if
there is any. If the patients fail to achieve near target blood glucose levels from diet and exercise
regiment, then pharmacotherapy is added to diet and exercise plan. Pharmacotherapy includes
oral anti diabetic drugs. Physicians must consider benefits of each drug against cost,
contraindications, degree of glycemic-lowering needed, ease of compliance, duration of action,
patient’s weight and patient’s lipid profiles.
The sulphonylureas and biguanides are the most commonly prescribed categories of
medications for oral anti diabetic therapy. They are safe, have better tolerability and superior
pharmacodynamic effects. Sulfonyl ureas stimulate the release of insulin from the pancreatic
islet cells via stimulation of receptors. Glipizide is one of the commonly prescribed anti diabetic
drugs from short acting sulphonyl urea category. Short acting sulphonyl urea drugs have some

96

advantages compared to long acting sulphonyl urea drugs. Short acting sulphonyl ureas are more
efficient in increasing meal-stimulated insulin secretion and have lower risk of hyperglycemia.
Glipizide was synthesized chemically in 1971 and has excellent safety profile. Glipizide
is an effective therapeutic agent for both first phase insulin secretion and for providing sustained
stimulatory response during long term treatment. Blood glucose concentration starts to decrease
within 30 min of ingestion of glipizide. Glipizide is 100 times more potent than tolbutamide.
Glipizide has uniform, rapid absorption throughout the gastro intestinal tract. Peak plasma
concentration of Glipizide is observed within 1-3h after single oral dose. Half life of Glipizide is
2 to 4 h in both intravenous and oral administration. Glipizide has no plasma accumulation
following repeated oral dosing. In spite of its clinical efficiency, Glipizide has poor patient
compliance because of its multiple daily dosing. Thus, it is appropriate to formulate Glipizide in
controlled release formulation. Glipizide is commercially available as controlled release
formulation.
Glipizide is a weakly acidic, water insoluble drug. It belongs to class II drugs of
biological classification system (BCS). Class II drugs have poor solubility and high permeability.
Commercial controlled release formulation of Glipizide uses osmotic drug delivery technology.
Commercial controlled release formulation of Glipizide is a coated bilayer tablet (Push-pull
system). One layer contains drug and the other layer contains osmogen and other ingredients
required to push the drug through the laser drilled hole. The tablet is coated with cellulose
acetate. Cellulose acetate is semi-permeable i.e., it is permeable only to water not for other
substances. Upon water entry into the tablet through semi-permeable membrane, the osmogens
dissolve and create osmotic pressure inside the tablet. Osmotic pressure drives the drug out of the
tablet through the laser drilled delivery orifice. Osmotic drug delivery systems are difficult to
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manufacture and they need special equipments for manufacturing. The objective of this work is
to develop bioequivalent formulation of Glipizide to its commercial formulation, Glucotrol® XL.
And, it is also of our interest to develop controlled release matrix formulation using carbopol as
release controlling polymer and hot melt granulation technology.
As mentioned in formulation development of propranolol hydrochloride, hot melt
granulation technique is a versatile technique offering many formulation options. However, the
excipients must be selected based on the properties of drug and the requirements of controlled
release. Following section presents rationale for selection of binder and fillers in the formulation

4.2. SELECTION OF FORMULATION COMPONENTS

4.2.1. Selection of binder
Glipizide is a poorly soluble weakly acidic drug. Glipizide has pH dependent solubility.
Solubility of the glipizide is 0.078 mg/ml in pH 6.8 and it is virtually insoluble in pH 1.2.
In hot melt granulation technique, waxy material is used as binder. Waxy binder can be either
hydrophilic e.g. Gelucire with higher HLB value or hydrophobic e.g. waxes with lower HLB
values. In this case, the objective is to formulation controlled release formulation of Glipizide
that is bioequivalent to osmotic delivery system of Glipizide. Osmotic delivery system has
constant release rate for 14 h. Therefore, the ingredients used in the formulation, must not
interfere with the dissolution of the drug as it may result in formulation that will have very low
release rate. If a hydrophobic wax is selected as binder in the formulation, then a dispersion of
drug in the hydrophobic wax will be formed. This will hamper the water availability for the
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dissolution of drug particles. Therefore, hydrophobic waxes must be avoided in the formulation.
Gelucire 50/13, a hydrophilic wax, is selected as binder for the formulation.

4.2.2. Selection of filler
Glipizide is a low dose drug. It is administered in three doses of 2.5 mg, 5 mg and 10 mg.
In this study, our objective is to develop bioequivalent formulation for 10 mg dose. However, it
is difficult formulate such a low dose without a filler. Fillers are available in various choices.
They are: (i) Water insoluble, non-swellable e.g. Dicalcium phosphate, (ii) Water insoluble,
water swellable e.g. Microcrystalline cellulose, (iii) Water soluble, non-swellable e.g. Lactose
monohydrate. As mentioned earlier, inclusion of water insoluble material will hamper the
availability of water to the drug dissolution. In order to achieve complete drug release from a
formulation containing poorly soluble drug, the excipients in the formulation should not interfere
with the drug dissolution. Therefore, dicalcium phosphate is not a good choice for filler and
either microcrystalline cellulose or lactose monohydrate can be selected as fillers.
Microcrystalline cellulose is depolymerized cellulose and has tremendous water uptake
capacity. Since microcrystalline cellulose promotes water influx into the system, the release
controlling mechanism in matrix tablet will be ruined. Matrix systems control the drug release by
modulating the water influx and controlling the drug efflux. Therefore, in order to compensate
for water influx, higher polymer concentration will be needed. This will increase the cost of the
delivery system. Hence, unless justified, microcrystalline cellulose is not a filler of choice. On
contrary, lactose monohydrate is water soluble filler and it dissolves slowly in water. Lactose
absorbs less water compared to microcrystalline cellulose however it does not impede the water
influx into the system like dicalcium phosphate. As lactose dissolves, it creates pores in the
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delivery system and these pores aid drug release. Since lactose dissolves slowly, the extent of
pore creation does not ruin the controlled release properties of release controlling polymer.
Therefore, lactose monohydrate is filler of choice for the formulation.

4.3. MATERIALS AND METHODS

4.3.1. Materials
Glipizide, Carbopol 971P (Noveon, Cleveland, OH), Gelucire 50/13 (Gattefosse,
Paramus, NJ), Lactose monohydrate (Foremost, Baraboo, WI), Microcrstalline cellulose (MCC)
(Avicel® PH-101) (FMC corporation, Philadelphia, PA).

4.3.2. Methods

4.3.2.1. Preparation of tablets
Hot melt granulation technique was used to prepare granules from the blend containing
appropriate quantities of Glipizide, Carbopol 971P, filler and Gelucire 50/13. Ingredients and
composition of formulations are given in the Table 4.1 and Table 4.2 respectively. Ingredients
of each formulation except the waxy binder were mixed for two minutes in the reverse mode at
1500 rpm prior in a Robot-Coupe® high shear mixer-granulator (Robot-Coupe Inc., Jackson,
MS). After blending, a circulating water bath was attached to the granulator bowl. Temperature
of the bowl was monitored using a digital thermometer. Once the temperature of the bowl
reached 60°C, waxy binder was added to the powder blend. Bowl temperature was kept at 60°C
during granulation. Granulation was carried out in the reverse mode at 1500 rpm for 2 min.
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Table 4.1. Ingredients of formulations for glipizide product development

Batch code

Filler

Tablet weight

Drug - polymer ratio

Polymerwax ratio

L-1

Lactose

100

1::0.5

1::1

L-2

Lactose

100

1::1

1::1

L-3

Lactose

400

1::0.5

1::1

L-4

Lactose

400

1::1

1::1

M-1

Avicel

400

1::1

1::1

M-2

Avicel

400

1::2

1::1

M-3

Avicel

400

1::4

1::1

M-4

Avicel

400

1::6

1::1
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Table 4.2. Compositions of formulations for glipizide product development

Batch code

Drug (%)

Carbopol (%)

Gelucire (%)

Filler (%)

L-1

10.00

5.00

5.00

80.00

L-2

10.00

10.00

10.00

70.00

L-3

2.50

1.25

1.25

95.00

L-4

2.50

2.50

2.50

92.50

M-1

2.50

2.50

2.50

92.50

M-2

2.50

5.00

5.00

87.50

M-3

2.50

10.00

10.00

77.50

M-4

2.50

15.00

15.00

67.50
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The resulting granules were passed through a 20-mesh sieve to remove any coarse granules while
they were still warm. The sieved granules were allowed to cool to room temperature. Tablets
from aforementioned granules were prepared using an 18-station rotary tablet press equipped
with 5/16” deep-concave punches and dies was used for tablet compression.

4.3.2.2. Evaluation of in vitro dissolution
Tablets were tested for its dissolution characteristics using USP apparatus II (paddle).
Hydrochloric acid (0.1 N, 750 ml) was used as the dissolution media for the first 2 hours. Then,
the pH of the dissolution media was adjusted to 6.8 using 250 ml of 1N tribasic phosphate
solution. Drug dissolution from the tablets was determined at 37°C at 50 rpm. Drug release from
the tablets was monitored using in situ fiber optic UV probes equipped with PDA (Photo diode
array) detectors (PION, Inc., Woburn, MA). Estimation of the drug concentration in the
dissolution media was based on single point calibration at 288 nm.

4.4. RESULTS AND DISCUSSION

4.4.1. Lactose based formulations
Composition of formulations with lactose as filler is given in the Table 4.2. Formulations
L – 1 and L -2 have 100 mg tablet weight. Both formulations contain different drug to polymer
ration. While L – 1 contains 1:0.5 drug-polymer ratio, L – 2 contains 1:1 drug to polymer ratio.
In vitro dissolution profiles of the formulations are presented in Figure 4.1. These 100 mg
sustained release tablets containing lactose as filler had long lag time. Only less than 20%
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Figure 4.1. Dissolution profiles of formulations containing lactose as filler†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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drug was released from the tablets till 8 h. Then, the matrix started to disintegrate and dump the
drug out. Within 12 – 14 h, the drug release from formulations was almost complete. This can be
attributed to higher solubility of lactose monohydrate compared to drug solubility. In phosphate
buffer, Lactose solubility is 148 µg/ml and the Glipizide solubility is 78 µg/ml. When dissolution
media enters into the matrix, there is a competition between the lactose and glipizide. Since
lactose has more solubility than glipizide, it dissolves faster than glipizide. This reduces the
availability of dissolution media for the dissolution of glipizide hence dissolution of glipizide. As
lactose continues to dissolve and leave the matrix, it creates pores that weaken the matrix
structure. In addition, dissolution of lactose increases the osmotic gradient and with draws more
dissolution media into the system. The continuous increase in osmotic pressure weakens the
matrix and results in matrix disintegration and dose dumping after certain time (8 h). Thus, the
100 mg formulations containing lactose as filler has two problems
i. Insufficient availability of the dissolution media for drug dissolution in the initial period
ii. Competitive reduction in drug dissolution.
Although competitive reduction in drug dissolution can not be rectified due to the lactose’s
higher solubility, dissolution media influx into the matrix can be increased. Increase is
dissolution media influx will provide more dissolution media for dissolution of drug hence
improve the drug release. Dissolution media influx can be increased by increasing the lactose
content in the formulation. Therefore, the tablet weight was increased to 400 mg by increasing
the lactose content in the formulations. However, for comparative purposes, the drug-polymer
ratio is kept at constant level of 1: 0.5 and 1:1 drug-polymer ratio.
Formulations L – 3 and L – 4 were 400 mg tablets containing drug – polymer ratio of
1:0.5 and 1:1 respectively. In vitro dissolution profiles of formulations L – 3 and L – 4 are given
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in Figure 4.1. As expected, 400 mg formulations containing more lactose released drug faster
than 100 mg formulations. No lag period was observed in drug release in dissolution media PH
6.8. However, the drug release was complete in less than 10 h. To be bioequivalent to osmotic
system of glipizide, the matrix formulation must have controlled drug release for 14 h. Faster
drug release from 400 mg lactose based formulations can be attributed to insufficient polymer
content to control the drug release. Therefore, by increasing polymer content or decreasing
lactose content, controlled release formulation of glipizide can be developed. And the filler
content and polymer content can be optimized to yield bioequivalent formulation of glipizide.
However, the controlled release from the formulation will be dependent on the controlling drug
solubility based on dissolution media influx in to the matrix tablets. In in vivo conditions,
composition, volume and pH of the gastric contents may change in fast and fed conditions. In
such circumstances, the dissolution profile glipizide from lactose based formulation will also
change. Therefore, the lactose based formulations are not robust. In addition, all formulations
using lactose as filler had picking problems and low tablet hardness (3 to 4 kps for 400 mg
tablets). Although it can be solved by addition of lubricants and glidants, no such attempts were
made as the release profiles from lactose based formulation lack scope for further development.

4.4.2. Microcrystalline cellulose based formulations
Filler of 400 mg formulations was changed to microcrystalline cellulose from lactose
monohydrate. Change of filler to microcrystalline cellulose yielded tablets with good hardness (9
to 11 kps) and no picking or sticking problem was observed during compression. However, as
expected, the drug release from microcrystalline cellulose based formulations was faster. This
can be attributed to increase in dissolution media influx into the system caused by the presence
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of microcrystalline cellulose. To control the influx of the dissolution media and efflux of the
drug, polymer content was increased and four formulations were prepared. The composition of
formulations is given in Table 4.2 and their release profiles are given in Figure 4.2.
Formulations M 1 to M 4 have differences in drug-polymer ratio. They had drug-polymer ratio of
1:1, 1:2, 1:3 and 1:6. Increase in drug – polymer ratio reduced the release rate. Formulation M4
containing 1:6 drug – polymer ratio had closest release profile to commercial formulation.
Bioequivalence of the microcrystalline cellulose based formulations were checked using F-2
values. F-2 values were calculated using following formula and drug release from commercial
formulation as reference.

1 n
f 2 = 50 log{[1 + ∑ wt ( Rt − Tt ) 2 ]− 0.5 × 100}
n t =1

(Eq.5.1)

Where n is the number of sampling time points used. In this study, n is equal to 10. Rt is the
actual cumulative percentage of acetaminophen released from the beads at each of the selected n
time points. Tt is the ANN model predicted cumulative percentage of acetaminophen released
from the beads at each of the selected n time points. wt is the optional weight factor. In this
study, wt is equal to 1.
When the two profiles are identical, f2 = 100. The f2 value is equal to 50 when an
average difference of 10% between the dissolution profiles that are being compared, is observed
at all time points used for the calculation of the f2 value. The FDA has set a public standard of f2
value between 50 and 100 to indicate similarity between two dissolution profiles. A formulation
is considered bioequivalent if the F2 values are above 50.
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Figure 4.2. Dissolution profiles of formulations containing MCC as filler†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Based on this criterion, formulation M – 4 containing drug – polymer ratio of 1:6 is
bioequivalent to commercial formulation. Although proven bioequivalent, formulation M – 4 had
incomplete drug release. Average drug release of 79.49% was observed at the end of 16 h.
Therefore, to maximize the drug release with out significantly changing F-2 value, artificial
neural network model was developed and optimization of the formulation composition was done
using genetic algorithm and artificial neural network model. Drug – polymer ratio of
microcrystalline cellulose formulations and their F2 values are given in the Table 4.3.

4.4.3. Formulation optimization

4.4.3.1. Artificial neural network modeling (ANN)
Artificial neural network modeling is an artificial intelligence based modeling tool. It
uses similar techniques to that of normal human learning behavior. That is, initially the trend in
the data is identified using a set of data called “training set” then the model is validated for
further use. It is commonly used by pharmaceutical scientists for solving various problems. Drug
release optimization is one of the challenging problems that will require ANN modeling.
Artificial neural network modeling is a versatile modeling tool. Both linear and nonlinear functions can be modeled using ANN. ANN models contain three components; input
layer, hidden layer and output layer. Input layer contains independent factors of the model and
the output layer contains dependent variables of the model. Hidden layer comprises of
mathematical transformations called neurons. Each neuron represents a mathematical
transformation. Neurons connect input layer and output layer. Independent variables are
mathematically transformed as they are connected with output layer through neurons.
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Table 4.3. F2 values of formulations M 1 to M 4

Batch code

Drug – polymer ratio

F – 2 value

M -1

1:1

19.59

M–2

1:2

22.84

M–3

1:4

33.66

M–4

1:6

52.16
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After the mathematical transformation, the relationship between input factors and output
loses logical meaning. Therefore, the ANN models have no statistical meaning hence sometimes
they are called “black box”. However, the predictability of the ANN models is superior to
conventional statistical models. The exceptional predictability of ANN models have been
attributed to selection of appropriate mathematical transformations and input scaling functions of
ANN modeling. When a set of input factors and output are presented to ANN model, the input
factors are scaled down to reduce the dimension of input space. These scaling functions are
called “squashing” functions and they convert the numerical values of inputs to symbols
representing low and high ranges of the input. For example, if the one of the inputs of ANN
model is 25, 40.60 and 75, then the range is fist computed and in this case it is 25 to 75. Low
value of 25 is assigned a value of -1 and the high value of 75 is assigned +1 and the values in
between take corresponding values in this scale. Squashing of inputs normalizes the inputs and
reduces the dimension. Following input scaling, the scaled inputs are transformed in hidden
layers. Transformation of scaled input is done by mathematical functions. There are many
mathematical functions that are used for transforming inputs and sigmoid transformation,
tansigmoid transformation, log transformation are few popular transformation functions.
Selection of mathematical function is dependent on the error distribution. That is, an appropriate
input transformation is selected to minimize the error in the training set. The data presented to
ANN model is generally segmented using random sampling in to three sets; training set, test set
and validation set. Initially, the transformation functions are selected based on the input-output
relationship in the test set and a random weight is added to the transformation functions. Then,
output values are predicted using an equation containing these transformations and randomly
generated weights. An error distribution is calculated from predicted values and actual output
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values in the test set. Then this error function is minimized by adjusting weights and/or changing
transformations. The modifications in weight and transformation functions are done till
maximum minimization of error function is achieved. This process of adjusting weights and
choosing transformation is called “training”. The training will stop once the error function
reaches minimum value. After the training stops, the ANN model can be validated using an
external validation set.
ANN model training is similar to human brain’s learning. That is, the relationship pattern
between inputs and outputs is studied from known examples (training set). However, ANN
model use mathematical functions with no logical justification unlike human brain where
relationship patterns are associated with logic. This difference in learning between human brain
and ANN model has advantage and disadvantage. Advantage is the numerical accuracy in
predictions which is higher than the human brain. Disadvantage is “overlearning”. Overlearning
is a process of extended training leading to selection of wrong input-output relationship pattern.
Overlearning happens when error in the data distribution “mislead” the ANN model to select
wrong transformation functions. This will result in learning from error rather than true inputoutput relationship. The outcome of “overlearning” is lack of generalization which is manifested
as least training error and high error in predictions with validation set. In most of the softwares
used for ANN model building, training schemes are tweaked to periodically consult with
independent validation set to stop the training process in early stages of training before
overlearning begins. One of the easiest tweaks in the training scheme to prevent overlearning is
“leave-one-out” cross validation. In “leave-one-out” cross validation, test set is divided into test
set and an internal validation set. While test set is used to adjust training weights, internal
validation set is used to terminate the training process before the overlearning begins. This
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process is continued by using validation set as part of training set and using another part of data
as validation set. This is one of the effective means for preventing over learning.

4.4.3.2. Formulation optimization using ANN
Objective of current ANN model is to identify the formulation that can release drug
completely. AI Triology® software program (Ward systems, Frederick, MD) was used for ANN
model building. AI Triology® uses backpropagation training and generalized regression training
algorithms. Earlier studies on selection of training algorithm for training indicate that generalized
regression algorithm had better generalization than backpropagation algorithm. Therefore, only
generalized regression algorithm was used for model development in this study. Following
model development and leave one out cross validation, ANN model showing least prediction
error was selected for formulation optimization. Genetic algorithm was used for formulation
optimization. Drug release profile of commercial formulation was used as reference. Constraints
were added on the later time points to support the optimization algorithm to find regions where
results that can fulfill the objective of the current study i.e., to yield a formulation that can
release the drug completely. Optimization based on ANN model yielded the formulation
composition containing 11.25% carbopol with 2.5% drug loading and 400 mg tablets containing
microcrystalline cellulose as filler. Figure 4.3 presents the comparison of predicted dissolution
profiles of ANN predicted formulation and the actual dissolution profiles of the ANN predicted
formulation. F – 2 values between these predicted and actual formulation was 74.34%. This
confirms the validity of the ANN model.
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Figure 4.3. Comparison of ANN predicted and actual dissolution profiles†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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4.4.3.3. Effect of compression force on the drug release
Literature reports that the drug release from carbopol matrix is sensitive to the
compression force. This is attributed to change in the interstitial space in higher compression
force. Higher the compression forces lower the interstitial space between polymer particles in the
tablet. This will boost the controlled release performance of the polymer. Thus it is of our
interest to test the effect of compression force on the drug release of ANN optimized
formulation. Therefore, 400 mg tablets containing 11.25% of carbopol and microcrystalline
cellulose as filler were compressed at two more additional compression forces of 1 mT and 1.5
mT. Although only marginal increase in tablet hardness was achieved, significant changes in the
in vitro dissolution profile was observed when the compression force was increased to 1 mT
from 0.5 mT. However, there is less changes in the drug release was observed when the
compression force was increased to 1.5 mT from 1 mT. Figure 4.4 presents the effect of
compression force on drug release profiles of the ANN predicted formulation. Table 4.4 presents
F-2 values of these formulations against commercial formulation. Formulation containing
11.25% of carbopol and microcrystalline cellulose as filler and prepared with both 1 mT and 1.5
mT were bioequivalent to commercial formulation.

4.5. CONCLUSIONS
Bioequivalent formulations of glipizide were prepared using carbopol – wax blends.
Lactose based formulations either released drug quickly or had long lag time. Lactose based
formulations had poor tablet hardness and picking problem during compression. Microcrystalline
cellulose based formulations yielded tablets with better hardness compared to lactose based
formulations and had no picking problem during compression. Drug release from
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Figure 4.4. Effect of compression force on dissolution profiles†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Table 4.4. F2 values of batches prepared using different compression forces

Compression force

F – 2 value

Drug release at 16 h

0.5 mT

41.42

96.41%

1 mT

58.47

83.07%

1.5 mT

50.89

79.65%
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microcrystalline cellulose based formulations was proportional to the drug – polymer ratio. Drug
release from microcrystalline cellulose based formulations was related to compression force used
to compress the tablets. Increasing the compression force reduced the extent of drug release and
yielded zero order release formulations.
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Chapter 5: Non Destructive Prediction of Dissolution Profiles Using NIRS

5.1. INTRODUCTION
Near Infrared Spectroscopy (NIR) has been used in the pharmaceutical industry for both
quality control and process monitoring at in-line, on-line and at-line locations to control the
quality attributes of products and by-products. It is an attractive quality control tool because of
its versatility, quickness and absence of sample preparation.
Literature suggests NIR can be used in various stages of tablet dosage form manufacture.
NIR can be used in raw material identification, determination of water content in raw materials,
identification of impurities or isomeric forms of raw materials, monitoring blend uniformity in
mixing operation, estimating granule size and density changes in granulation process, measuring
the rate of drying in the drying operation, estimating hardness, drug content, disintegration and
dissolution of tablets, monitoring coating thickness in coating operation etc.
In spite of the availability of substantial evidence from literature on use of NIR in tablet
manufacturing, measurement of dissolution from sustained release dosage form is an unexplored
territory. Primary reason is that drug dissolution is a complex process dependent on many
properties of the delivery system and dynamic changes occurring during the drug release. Drug
dissolution rate depends on the type of dosage form (compressed/coated), solubility of the drug
and interaction between drug and other excipients in tablet. NIR spectrum of a tablet contains
sparse information about polymer characteristics, tablet hardness, water content, drug
concentration etc. These properties can have a direct relationship with the rate of drug
dissolution. However, the initial properties of tablets such as drug content, water content,
hardness, density will change during the dissolution process. These changes are time and
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concentration dependent. Thus, the challenge in modeling drug dissolution with near infrared
spectrum is the lack of complete information about dissolution process per se in the spectrum.
However, if these changes are directly related to the initial properties of the system, then a valid
relationship must exist between NIR spectrum and dissolution profile. This relationship may be
linear or nonlinear depending on drug release kinetics. If the drug release is independent of time
(Zero order), then initial concentration of the ingredients determine rate of drug release and the
rate of drug release remains constant till the end of dissolution period. In such circumstances
(zero order release), the relationship between NIR spectrum and drug release profile might be
linear. If however, the drug release rate changes with time, then NIR spectrum-drug release
profile relationship could be non-linear or may have no correlation.
Generally, drug release from sustained release matrix tablet is directly proportional to
polymer concentration. However, polymer erosion, changes in drug concentration gradient,
changes in drug diffusion path, changes in matrix integrity and tortousity can distort in the NIR
spectrum-dissolution profile relationship, thus resulting in poor predictability of NIR models.
Higuchi’s square root time dependent release kinetics is the most common nonlinear drug release
pattern observed in sustained release hydrophilic matrix tablets. In some cases, part of the drug
dissolution profile is linear and the other part is nonlinear. That is, drug release rate remains
constant in one part of the dissolution profile and release rate varies in the other part of the
dissolution profile.
For modeling such complex relationships, multivariate regression models must estimate
the spectral variability caused not only by the initial properties (hardness, thickness, moisture
content, etc.) of the tablets, but also extract relevant information from the spectrum that has
relationship with the drug dissolution from the tablets. For example, the initial drug release might
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be related to tablet hardness, however, in the later stages, as polymer hydrates, initial tablet
hardness may not have any relationship with drug release. Since physical properties of the tablets
and chemical nature of polymer influence the drug release interactively, it is difficult to attribute
the changes to a specific peak in NIR spectrum. Rather, the spectral variance in a region can
have relationship and this region can only be identified during calibration model building. Such
modeling tasks are computationally intensive. Thus, selection of appropriate algorithm to
complete the task quickly with no compromise on predictability of the model is important. This
poster presents a comparison of multivariate modeling algorithms such as Partial Least Square,
Support Vector Machines (SVM) and K-Nearest Neighbors (KNN). Partial Least Square (PLS)
technique is well known in the pharmaceutical world and most commonly used NIR modeling
technique. The other two techniques are uncommon in pharmaceutical industries, but have been
used in food, agriculture, and business intelligence sectors. SVM and KNN are useful in special
circumstances where non-linear, multivariate predictor-response relationship cannot be
effectively modeled using PLS. This poster presents a comparison of prediction power of these
three algorithms to estimate drug dissolution from sustained release matrix tablets containing
propranolol hydrochloride.

5.2. MATERIALS AND METHODS

5.2.1. Materials
Propranolol hydrochloride, Carbopol 971P NF (Noveon Inc.,Cleveland, OH), Eudragit L
100 – 55 (Degussa Rohm Pharma Polymers, Piscataway, NJ), glyeryl monostearate (Stepan,
Northfield, IL), Gelucire 50/13 (Gattefosse corporation, Paramus, NJ).
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5.2.2. Methods

5.2.2.1. Granulation
Hot melt granulation technique was used to prepare granules from the blend containing
appropriate quantities of propranolol HCl, Carbopol 971P, Eudragit L-100-55, glyceryl
monostearate (GMS) and Gelucire 50/13. A total of fifteen formulations were prepared by
changing the composition of the aforementioned ingredients. Compositions of formulations are
given in Table 5.1. The batch size of each formulation was 300 g. A blend of waxy binder was
prepared by melting GMS and Gelucire 50/13 at 60°C. The molten mass was mixed thoroughly
and poured on a metal tray, and allowed to cool to room temperature. The resulting waxy sheet
was cut into small size flakes, which were then used as a waxy binder for the hot melt
granulation technique.
Ingredients of each formulation except the waxy binder were mixed for two minutes in
the reverse mode at 1500 rpm prior in a high shear mixer-granulator (Robot-Coupe® Inc.,
Jackson, MS). After blending, a circulating water bath was attached to the granulator bowl.
Temperature of the bowl was monitored using a digital thermometer. Once the temperature of
the bowl reached 60°C, waxy binder was added to the powder blend. Bowl temperature was kept
at 60°C during granulation. Granulation was carried out in the reverse mode at 1500 rpm for 2
min. The resulting granules were passed through a 20-mesh sieve to remove any coarse granules
while they were still warm. The sieved granules were allowed to cool to room temperature.
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Table 5.1. Composition of formulations

Formulation†
Code

Glyceryl
monostearate
(%)

Gelucire®
50/13
(%)

Carbopol®
971 P
(%)

Eudragit®
L-100-55
(%)

Di-Tab®
(%)

PD-1

7.5

2.5

5

0

85

PD-2

7.5

2.5

5

20

65

PD-3

7.5

2.5

10

10

70

PD-4

7.5

2.5

15

0

75

PD-5

7.5

2.5

15

20

55

PD-6

5

5

5

10

75

PD-7

5

5

10

0

80

PD-8

5

5

10

10

70

PD-9

5

5

10

20

60

PD-10

5

5

15

10

65

PD-11

2.5

7.5

5

0

85

PD-12

2.5

7.5

5

20

65

PD-13

2.5

7.5

10

10

70

PD-14

2.5

7.5

15

0

75

PD-15

2.5

7.5

15

20

55

† 400 mg tablets containing 80 mg of propranolol hydrochloride were compressed at two
compression forces - 0.6 mT and 1.2 mT.
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5.2.2.2. Tabletting
Tablets weighing 400 mg and containing 80 mg of propranolol HCl were prepared by
compressing the aforementioned granules. An 18-station rotary tablet press equipped with 3/8”
flat-faced punches and dies was used for tablet compression. Each formulation was compressed
at two compression forces, 0.6 mT and 1.2 mT. A total of fifteen formulations, each compressed
at two different compression forces yielded 30 batches of tablets. Three tablets from each batch
were randomly selected for NIR measurements.

5.2.2.3. NIR spectroscopy
NIR spectrum (from 400 nm to 2500 nm) of each tablet was taken from both sides using
the Rapid Content Analyzer (Foss NIRSystems, Silver Spring, MD) in the reflectance mode.
Constant spot size of light impingement of 9.25 mm was used for spectral measurements of all
batches. Thirty two co-added scans were taken for each tablet to improve the signal-to-noise
ratio, and they constitute one spectrum. Unprocessed NIR spectrum was exported to MicrosoftExcel®. The unprocessed spectrum for each tablet contained 4200 absorbance values, each taken
at 0.5 nanometer gaps in the range of 400 nm to 2500 nm.

5.2.2.4. In vitro dissolution study
Following NIR spectral measurement, each tablet was tested for its dissolution
characteristics using USP apparatus II (paddle). Hydrochloric acid (0.1 N, 750 ml) was used as
the dissolution media for the first 2 hours. Then, the pH of the dissolution media was adjusted to
6.8 using 250 ml of 1N tribasic phosphate solution. Drug dissolution from the tablets was
determined at 37°C at 50 rpm. Drug release from the tablets was monitored using in situ fiber
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optic UV probes equipped with PDA (Photo diode array) detectors (PION, Inc., Woburn, MA).
Estimation of the drug concentration in the dissolution media was based on single point
calibration at 288 nm. Drug dissolution profiles of all batches were calculated based on the UV
absorbance, theoretical drug content, and volume of the dissolution media using Indigo®
software (PION, Inc., Woburn, MA).

5.2.2.5. Modeling
Statistical models for correlating the NIR spectrum of 30 batches and their dissolution
profiles were developed using STATISTICA® QC&Text miner (Statsoft, Tulsa, OK). Three
regression modeling techniques such as PLS (Partial Least Square), SVM (support vector
machine) and KNN (K-nearest neighbors) regression were used for screening purposes.
For selection of the best algorithm, regression coefficient of the observed versus
predicted values were used. The best algorithm should have a high regression coefficient. The
best algorithm was then used for building prediction models and validation. NIR spectral data
from Formulation 13 were used as the validation set and hence they were not used in the while
building the calibration model. Thus, calibration models were built using the remaining 14
formulations. These 14 formulations were randomly sampled and divided into 2 sets, namely
training set (75%), and test set (25%). Calibration models were built and optimized using the Vfold cross validation protocol. In the V-fold cross-validation, repeated (v) random samples are
drawn from the training and test sets, and the respective model is then applied to compute the
predicted values. A regression coefficient of 0.90 for calibration models was used as the
predefined selection criteria for algorithm selection.
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5.3. RESULTS AND DISCUSSION

5.3.1. Algorithm screening

5.3.1.1. PLS modeling
In conventional PLS modeling, calibration model is built to correlate spectral data with
one output. However, dissolution profile is a repeated measure data, i.e., measurement of drug
released from a single tablet over time. Owing to constraints of the PLS modeling, the entire
dissolution profile cannot be modeled with one PLS model. Thus, for algorithm screening
purposes, three calibration models were built to correlate the NIR spectrum and drug released at
2 h, 12 h and 24 h respectively. The models for predicting the amount of drug dissolved at 2 h,
12 h and 24 h were named Y-2, Y-12 and Y-24 respectively. Regression coefficients of Y-2, Y12 and Y-24 were 0.839, 0.853 and 0.871 respectively indicating that only 83.9%, 85.3% and
87.1% of variance in the dissolution profiles were explained by these models. Y-2, Y-12 and Y24 models included 8, 5 and 8 latent vectors respectively. Number of latent vectors was selected
based on the requirement of vectors required to explain 99.5% of variance observed in the data
set.
Initially, selection of number of latent vector for global PLS model (model including
entire spectrum) was based on cross-validation. Then, this number was optimized by screening
different regions of spectum having maximum correlation with the response (amount of drug
dissolved). This was done to improve the predictability of the model as this procedure removes
noisy regions from model input.

126

NIR spectrum as mentioned earlier is a multivariate spectrum. Spectral noise and
irrelevant information (unrelated to the response) in the spectrum can reduce the predictability of
the calibration model. These effects can be removed from the spectrum by scanning the spectrum
in predefined windows (wave length ranges). For example, the entire spectrum in the range of
400 to 2500 nm (4200 absorbance readings) can be divided in to 20 windows each with 210
absorbance readings. Selection of window size depends on the complexity of the predictorresponse relationship. Complex relationships might demand multiple windows be combined for
final prediction models. 20 windows is generally an optimum setting for screening as suggested
by the literature. PLS models built using a region of wavelength of the entire spectrum (window)
are local models, however, containing maximum information about the response of interest.
Interestingly, Y-2, Y-12, Y-24 prediction models had the following overlapping window regions:
2200 to 2394.5 nm for Y-2, 2185 to 2289.5 nm for Y-12, 2185 to 2289.5 nm for Y-24. In NIR
spectrum, spectral region starting from 2200 nm has characteristic bands for –CH, -CH2 and –
CH3 groups. This could be attributed to polymers in the system. Release controlling polymers in
the tablets used in this study were Carbopol and Eudragit. These two are acrylic acid derivatives.
Carbopol is prepared by crosslinking acrylic acid monomer CH2CH(COOH) using allyl sucrose.
Thus, spectral characteristics indicate a relationship between polymer content and drug release.
However, the models did not have enough predictive power as judged by the pre-defined
selection criteria. This could be attributed to limitations of the PLS modeling algorithm. PLS
assumes linear relationship between predictors and response. As described earlier, linearity in the
spectrum-dissolution profile can be distorted due to many factors. Thus, models that can account
for nonlinearity in the spectrum-dissolution profile relationship could perform better. Hence,
Support Vector Machine/Support Vector Regression algorithm was tested.
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For, literature provides evidence for model development using support vector machines where
nonlinearity in predictor-response relationship had ill-influence on model predictability.

5.3.1.2. SVM modeling

5.3.1.2.1. Theory
Support vector machines (SVM) are based on concept of hyperplanes and decision
boundaries. SVM algorithm maps the predictor variables and isolates them in hyper planes. For
segregating (mapping) the predictor variables, decision boundaries are used in SVM. SVM was
initially developed for classification tasks. In a simple classification task, assume that two
objects with different qualities (e.g. blue and red) are present in a two dimensional plane (e.g. a
flat surface). Geometrically defined place where the objects are present is called input space. To
separate them, we must find the boundary line that can separate these two objects in the input
space. This is analogous to drawing a line in a two dimensional plane to separate the blue and red
objects. The process of drawing a decision line to separate objects in a hyper dimensional plane
is called mapping. If a straight line is used for input mapping, then the line is called linear
classifier. This forms the basis for statistical learning algorithms. This simple learning algorithm
does not have enough power to explain multidimensional data (spectra data set) due to the data
dimensionality, complexity, data density and colinearity characteristics. These difficult learning
tasks are effectively handled by kernel learning algorithms such as SVM, multiple layer
perceptron, etc.
In SVM, decision boundaries, instead of decision lines (used in linear regression), are
used for input mapping. For classification task in a multidimensional space, it is ideal to select a
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hyper plane (decision line with boundaries) that correctly classifies the data, i.e., with a
maximum distance to dissimilar objects. This distance between dissimilar objects is called a
margin. Ideally, maximum margin must be achieved to facilitate accurate classification of a new
data set. Thus, in a model training session, we must identify the hyperplane for separation of
objects and maximizing the margin. Once identified and optimized, such hyperplanes are called
maximum-margin hyperplanes or decision boundaries or optimal hyperplanes. Training set
vectors that are close to the optimal hyperplanes are called support vectors. Optimal hyperplane
provides probabilistic test error that is minimized when the margin is maximized.
Before mapping, predictors are spread in input space (multidimensional ill-defined
hypothetical space). After mapping with decision boundaries, the SVM algorithm converts the
input space into feature space (well defined space with less dimensions compared to input
space). This process is known as dimensionality reduction. This is a common concept in
Machine Learning Theory. Dimensionality reduction improves generalization and reduces
computational burden.
In order to learn nonlinear predictor-response relationship using linear machines, the
machine learning theory suggests usage of fixed non-linear mapping transforms that project data
into a feature space. Then a linear machine is used to classify them in the feature space.
However, such tasks are computationally intensive. Computational burden of such task can be
reduced using kernels. Kernals are mathematical functions that transform data implicitly (in
input space itself) into a feature space and train a linear machine in input space. Thus, concept of
kernels is pivotal in machine learning algorithms, and SVM is one of the machine learning
algorithms. Four types of kernels are commonly used in SVM regression: linear, polynomial,
radial basis function and sigmoid.
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In SVM regression, a non-linear function is learned by a linear learning machine in a kernelinduced feature space, while the capacity of the system is controlled by a parameter that does not
depend on the dimensionality of the space. In any regression technique, a relationship between
predictors and responses is assumed and expressed by a function and noise term.

y = f(x) + noise

(Eq. 5.1)

Now, the task is to find a functional form for f that can correctly predict new cases that
the SVM has not been presented with during training. This is achieved by training the SVM
model using training set and optimizing the error function and decision boundaries. The
functional form of predictor-response relationship in SVM regression includes kernels, slack
variables and weight vectors. Kernels are used for feature mapping and slack variables are used
for defining geometrical margins of decision boundaries to improve generalization. Slack
variables are the measure of error on training data points. Hence, selection of appropriate kernel
and optimization of training parameters yield functional form of predictor-response relationship.
Parameters in the functions are optimized using cross-validation during model training. Cross
validation prevents “over learning” of the model. “Over learning” is the process by which the
accuracy of trend identification is hampered by error present in the data. “Over learning”
significantly affects the predictability of the model. Model may continuously over predict or
under predict when “over learning” happens during model building. “Over learning” can be
prevented using cross validation during training process.
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5.3.1.2.2. Results
SVM models for Y-2, Y-12, and Y-24 were developed with linear, polynomial and radial
basis function kernels. Degree of polynomials was optimized for each model. Polynomial degree
of 2 was optimal for the Y-2, Y-12 and Y-24 models as increase in polynomial degree did not
provide any improvement in regression coefficients. Regression coefficients for Y-2 models with
linear, polynomial and RBF kernels were 0.814, 0.710 and 0.773 respectively. Regression
coefficients for Y-12 models with linear, polynomial and RBF kernels were 0.805, 0.704 and
0.824 respectively. Regression coefficients for Y-24 models were 0.790, 0.659 and 0.783. It can
be inferred that SVM based on linear and RBF kernels had better explanatory power than models
with polynomial kernel. However, the regression coefficients of models with linear and RBF
kernels were lower than that of the PLS models. This implies that in spite of their sophisticated
kernel based input mapping principle, SVM regression failed to offer better predictability than
the PLS models. This could be attributed to predictor variance distribution. PLS model had
specific predictor regions (windows) as model input. This region had maximum correlation with
out puts; hence prediction errors caused by noisy inputs were eliminated. However, SVM uses
the entire spectrum for modeling. Owing to “Garbage in-Garbage out” modeling principle, when
noisy variables having little or no correlation with outputs are used as predictors, the model
predictability is less. Thus predictability can be improved by selecting a spectral region that has
maximum correlation with the cumulative amount of drug release. In addition, default training
parameters were used for model training in this study. If the training parameters are optimized
for each kernel type, then predictability could improve. Based on better predictability of linear
kernels, it can be inferred that the predictors have valid linear relationship with responses. This
means, the drug release (response) has a linear relationship with variance observed in the NIR
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spectrum (predictor). If the variance in the NIR spectrum is directly related to the concentration
of the polymers and excipients, then the drug release is directly related to polymer and excipient
concentration.

5.3.1.3. KNN modeling

5.3.1.3.1. Theory
K-Nearest neighbor (KNN) models are based on combination of local models. This
means that the statistical analysis for the whole data set is split into local analyses and then
combined. Predictors and responses of the training set are sampled and distance function is
introduced between predictors. This distance function defines each predictor value. Then a
neighborhood is formed by the predictors that are close to one another in terms of the distance
between predictor values. In KNN, response from an unknown predictor is calculated by using
the group of predictor values (neighborhood) that are close to the unknown predictor value. Thus
predictability of the KNN model depends on the K value that defines number of elements in each
neighborhood. Once the neighborhood of the unknown predictor value is identified, the predicted
response will be the arithmetic mean response value of responses of predictor values in the
neighborhood. KNN model fits data closely which might lead to overfitting, i.e., poor
predictability caused by lack of generalization of the calibration model. Thus, distance function
and cardinality of the neighborhood (K) must be carefully selected for building models with
better predictability. K value is an indicator of adoptability of the model. Higher the K value,
poorer the predictability. If the K value is small, then the model lacks generalization power to
predict new cases. Optimal K value can be selected using V-fold cross-validation. In V-fold
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cross-validation, the number of folds (subsets of training data) is defined. For example, if the
data is set to be divided into 10 folds, 10 subsets are created using random sampling. Then, 9
subsets (number of folds minus one) will be used for training, and the unused set serves as the
internal validation set. Prediction error of the model developed using 9 subsets, for the internal
validation set is monitored to stop the training process. In the beginning of the training, the
prediction error decreases as an appropriate K value is achieved. Then, if the K value continues
to increase, the prediction error also starts to increase, thus indicating data overfitting. The
training is terminated when the prediction error starts to increase, and the K value required for
least prediction error is selected as the optimal K value. This process is repeated by swapping the
internal validation set from one training subset. Thus, in the second iteration, a new internal
validation serves to prevent overfitting. Once all the training subsets have served as internal
validation sets, the training error is calculated by averaging errors observed in each iteration.

5.3.1.3.2. Results
KNN models were developed using four different types of distance measures, namely
Euclidean, Euclidean squared, Cityblock and Chebychev. Numbers of nearest neighbors were
optimized using V-fold cross-validation for each distance measure. Cityblock distance measure
and three nearest neighbors were identified as the best distance training settings in terms of
predictability. Regression coefficients for Y-2, Y-12 and Y-24 models were 0.972, 0.964 and
0.979. These regression values satisfied pre-set selection criteria of 0.9 for prediction models.
Thus, KNN algorithm was used to model the drug dissolution profile, i.e., amount of drug
released at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h, 16 h, 18 h, 20 h, 22 h and 24 h. The KNN
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algorithm can handle multiple outputs. Thus, only one model was with Cityblock distance
measure and three nearest neighbors was developed.

5.3.2. Model validation
KNN model was developed for predicting the entire dissolution profile using Cityblock
distance measure. Observed and predicted values for the dissolution data obtained from
Formulation 13 for both low and high compression forces are given in Figure 5.1. and Figure
5.2, respectively. The regression coefficients between observed and predicted values were 0.984
and 0.981 for formulation 13 prepared at low and high compression forces respectively.

5.4. CONCLUSION
Dissolution profiles of propranolol hydrochloride from sustained release matrix tablets
were predicted from NIR spectra of tablets. Selection of algorithm was important to achieve the
best predictability. K-nearest neighbor algorithm had better predictability than partial least
square and support vector machine algorithms.
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Figure 5.1. Validation using formulation 13 prepared at 0.6 mT†
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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Figure 5.2. Validation using formulation 13 prepared at 1.2 mT
† Each data point represents average of three measurements. Standard deviation of three
measurements is presented as error bars.
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